Skip to content
Evigrade

Edoxaban

AEMPS

Direct oral anticoagulants (factor Xa inhibitors)

ATC code: B01AF03

Brand names: Savaysa

Updated · Methodology

Indications

A

Non-valvular atrial fibrillation

First line

Edoxaban is a direct oral anticoagulant (DOAC) that inhibits factor Xa; in Spain it is sold as Lixiana. In non-valvular atrial fibrillation it is prescribed to prevent stroke and systemic embolism. Per the AEMPS ficha técnica, the indication covers adults with one or more risk factors such as heart failure, hypertension, age 75 or older, diabetes, or prior stroke or TIA. The 2024 guidelines prefer DOACs over vitamin K antagonists, except in patients with a mechanical valve or moderate to severe mitral stenosis. In ENGAGE AF-TIMI 48 (NEJM 2013, 21,105 patients), edoxaban 60 mg was noninferior to warfarin: stroke or systemic embolism occurred at 1.18 versus 1.50 percent per year, with less major bleeding (2.75 versus 3.43 percent per year) and less intracranial bleeding (0.39 versus 0.85 percent). The usual dose is 60 mg once daily. It drops to 30 mg once daily with at least one of three factors: creatinine clearance 15–50 mL/min, body weight 60 kg or less, or concomitant ciclosporin, dronedarone, erythromycin or ketoconazole. Below 15 mL/min and on dialysis it is not recommended. In ENGAGE AF, efficacy against well-controlled warfarin was lower at higher creatinine clearance. With high clearance the ficha therefore asks for a careful assessment of thrombotic and bleeding risk first, and the label (Savaysa) says not to use edoxaban above 95 mL/min. According to the ficha there is no specific antidote. In Spain the 2016 AEMPS document sets out when the public health system prescribes DOACs, for example when INR control on a vitamin K antagonist is poor.

ICD-10: I48.9 · ICD-11: BC81.3

A

Venous thromboembolism

First line

Edoxaban is a direct oral anticoagulant that inhibits factor Xa. Per the AEMPS ficha técnica it is used to treat deep vein thrombosis (DVT) and pulmonary embolism (PE) and to prevent their recurrence in adults. The CHEST 2021 guideline and the 2019 pulmonary embolism guidelines prefer DOACs, edoxaban included, over vitamin K antagonists. The regimen differs from apixaban and rivaroxaban: a parenteral anticoagulant such as low-molecular-weight heparin is given for at least 5 days first, and only then edoxaban 60 mg once daily, without overlap. The 30 mg dose follows the same criteria as in atrial fibrillation: creatinine clearance 15–50 mL/min, body weight 60 kg or less, or ciclosporin, dronedarone, erythromycin or ketoconazole. In Hokusai-VTE (NEJM 2013, 8,292 patients), recurrent VTE occurred in 3.2 percent on edoxaban and 3.5 percent on warfarin, with less clinically relevant bleeding (8.5 versus 10.3 percent). Treatment length depends on the cause: at least 3 months after a transient trigger (surgery, trauma, immobilization), longer with permanent risk factors or unprovoked thrombosis. In hemodynamically unstable PE and in candidates for thrombolysis or embolectomy, edoxaban does not replace unfractionated heparin. In antiphospholipid syndrome with prior thrombosis DOACs are not recommended, especially with triple positivity. In active cancer, Hokusai VTE Cancer (NEJM 2018) found fewer recurrences with edoxaban than with dalteparin (7.9 versus 11.3 percent) but more major bleeding (6.9 versus 4.0 percent). The ficha states that efficacy and safety in active cancer have not been established, so benefit and bleeding risk are weighed case by case.

ICD-10: I82.9 · ICD-11: BD71

Marketing claims without evidence base

The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.

F

COVID-19

Not recommended

Edoxaban is a direct oral anticoagulant prescribed for atrial fibrillation and venous thrombosis. In 2020–2022 there was debate about giving oral anticoagulants in COVID-19 «to prevent clots». In outpatient COVID-19 and after discharge, such use has not improved survival or reduced hospitalization. Edoxaban itself was tested in the HERO-19 RCT (JAMA Network Open 2026): 139 hospitalized patients received therapeutic-dose low-molecular-weight heparin in hospital and edoxaban 60 mg after discharge up to day 42, while the control group received prophylactic heparin and then placebo. Death or thromboembolism occurred in 21 versus 29 percent, a difference compatible with chance (HR 0.74; 95% CI 0.38–1.48). In outpatients, apixaban in ACTIV-4B (JAMA 2021) did not reduce hospitalizations, thrombosis or deaths either, and the trial was stopped early because of too few events. The 2023 Cochrane review of non-hospitalized people found little or no difference in mortality, hospitalization or major bleeding with prophylactic anticoagulants, and probably fewer venous thromboembolic events (1 versus 3 percent), based on short-term data only. The ASH guidelines (Blood Advances 2025) suggest against routine anticoagulant prophylaxis after discharge. In hospital, prophylaxis is given with heparins when indicated. People already taking edoxaban for another indication should not stop it on their own during COVID-19. Taking it «just in case» adds bleeding risk without proven benefit. If edoxaban was prescribed for COVID-19 «to prevent clots», consider seeking a second opinion.

ICD-10: U07.1 · ICD-11: RA01.0

F

Mechanical heart valve

Not recommended

Edoxaban is a direct oral anticoagulant prescribed for non-valvular atrial fibrillation and venous thrombosis. With a mechanical heart valve it is not recommended. The AEMPS ficha técnica (section 4.4) says edoxaban has not been studied in patients with mechanical valves, in the first 3 months after a bioprosthetic valve or in moderate to severe mitral stenosis, so its use in these patients is not recommended. The 2021 /EACTS guidelines give direct anticoagulants in mechanical valves a class III recommendation. Class data exist: RE-ALIGN (NEJM 2013) with dabigatran was stopped early because of excess thromboembolic events and bleeding, and PROACT Xa (NEJM Evidence 2023) with apixaban in patients with an On-X aortic valve was stopped because of excess valve thrombosis and thromboembolism. With a mechanical valve the anticoagulant of choice is a vitamin K antagonist; in Spain that means acenocoumarol (Sintrom) or warfarin (Aldocumar). The cardiologist sets the target INR by the thrombogenicity of the prosthesis and the patient's risk factors. If a person already takes edoxaban, for example for atrial fibrillation, and receives a mechanical valve, the doctor plans the switch to a vitamin K antagonist without a gap in anticoagulation. The ficha describes this transition with a reduced edoxaban dose. If edoxaban was prescribed with a mechanical heart valve, consider seeking a second opinion.

ICD-10: Z95.2 · ICD-11: QB50.21

How to read tiers A–F
  • AStrong evidence – first or second line in international guidelines
  • BRecommended in selected cases
  • CStudy data contradict each other
  • DBenefit not proven, no documented harm
  • FDocumented harm, or risk without benefit

Mechanism of action

A direct inhibitor of activated clotting factor Xa. Edoxaban binds free factor Xa selectively and reversibly and inhibits prothrombinase, so less thrombin forms and clots build more slowly. The effect starts within 1 to 2 hours, together with peak concentration. Bioavailability is about 62 percent, and about 55 percent is bound to plasma proteins. Most of the drug circulates unchanged: carboxylesterase 1 hydrolyzes part of it, and oxidation by CYP3A4/5 accounts for less than 10 percent. Edoxaban is a P-glycoprotein substrate, and its interactions with inhibitors and inducers run through this transporter. The kidneys account for about half of total clearance, and the half-life is 10 to 14 hours. Routine coagulation monitoring is not needed, and INR and aPTT are not useful for judging the effect.

Safety

Boxed warning

FDA boxed warning (Savaysa): in non-valvular atrial fibrillation edoxaban should not be used with creatinine clearance above 95 mL/min, because in ENGAGE AF-TIMI 48 these patients had more ischemic strokes on 60 mg than on warfarin. Premature discontinuation of any oral anticoagulant without adequate alternative anticoagulation increases the risk of ischemic events. With neuraxial anesthesia or spinal puncture, epidural or spinal hematomas may occur and may cause long-term or permanent paralysis.

Contraindications

  • Hypersensitivity to edoxaban or any excipient
  • Active clinically significant bleeding
  • Liver disease with coagulopathy and clinically relevant bleeding risk
  • Lesions with a significant risk of major bleeding: active or recent gastrointestinal ulcer, malignancy at high bleeding risk, recent brain or spinal injury or surgery, recent eye surgery, recent intracranial hemorrhage, esophageal varices, arteriovenous malformations, aneurysms
  • Severe uncontrolled hypertension
  • Concomitant use of another anticoagulant, except when switching or when heparin keeps a central catheter open
  • Pregnancy and breastfeeding

Serious adverse effects

  • Major bleeding, including fatal bleeding
  • Intracranial hemorrhage (uncommon), subarachnoid and subdural hemorrhage (rare)
  • Intraocular hemorrhage (uncommon), pericardial and retroperitoneal hemorrhage (rare)
  • Anaphylactic reaction and allergic edema (rare)
  • Anticoagulant-related nephropathy (frequency not known)
  • Complications of severe bleeding: compartment syndrome, kidney failure from hypoperfusion

Common adverse effects

  • Nosebleeds (7.7%)
  • Blood in the urine (6.9%)
  • Anemia (5.3%)
  • Gastrointestinal, oral and pharyngeal bleeding
  • Bleeding into the skin, bleeding at puncture sites
  • Vaginal bleeding, heavier or longer periods
  • Dizziness, headache
  • Abdominal pain, nausea
  • Rash, itching
  • Raised bilirubin and GGT, abnormal liver tests

Pregnancy: can you take Edoxaban?

Contraindicated in pregnancy (AEMPS ficha técnica, sections 4.3 and 4.6). Safety in pregnant women has not been established, edoxaban crosses the placenta, animal studies showed reproductive toxicity, and the drug carries its own bleeding risk. Women of childbearing potential should avoid pregnancy during treatment. If pregnancy is planned, the anticoagulant is changed in advance together with the doctor who manages the treatment.

Breastfeeding: can you take Edoxaban?

Contraindicated during breastfeeding (AEMPS ficha técnica, sections 4.3 and 4.6). Safety during breastfeeding has not been established, and in animals edoxaban passes into milk. The choice is between stopping breastfeeding and stopping treatment. The FDA label also advises against breastfeeding during treatment because of the risk of bleeding in the infant.

Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.

Renal dose adjustment for all the patient's drugs

Enter the patient's kidney function and drugs. On one page you'll see the dose each label gives

Edoxaban prescribing information (FDA) →

Practical notes

Timing and administration

Edoxaban is taken once a day, with or without food. If a dose is missed, it is taken as soon as remembered, and the usual schedule continues the next day. Two doses are not taken on the same day to make up for it. The tablet can be crushed, mixed with water or apple puree and swallowed straight away, or suspended in a little water and given through a nasogastric tube (AEMPS ficha técnica, section 4.2).

Monitoring

INR monitoring is not needed. Before treatment starts, creatinine clearance is calculated with the Cockcroft-Gault formula: it sets the dose, 60 or 30 mg, and below 15 mL/min edoxaban is not recommended. Kidney function is checked again whenever it may change, for example with dehydration or with certain medicines. Liver tests are done before the start and periodically if treatment lasts more than a year. Hemoglobin and hematocrit help detect hidden bleeding (AEMPS ficha técnica, sections 4.2 and 4.4).

Special situations

Before surgery or an invasive procedure, edoxaban is stopped as early as possible, preferably at least 24 hours before. It is restarted once bleeding is under control, bearing in mind that the effect begins 1 to 2 hours after a tablet. Edoxaban has no specific antidote. For life-threatening bleeding the ficha describes four-factor prothrombin complex concentrate at 50 IU/kg, which reversed the effect 30 minutes after the end of the infusion. Hemodialysis removes very little of the drug. When switching from a vitamin K antagonist, acenocoumarol or warfarin is stopped and edoxaban is started once INR is 2.5 or lower (AEMPS ficha técnica, sections 4.2, 4.4 and 4.9).

Drug–drug interactions

32 pairs found. Sorted from critical to minor.

CriticalAcenocoumarolVitamin K antagonist anticoagulants

Mechanism

Edoxaban directly and reversibly inhibits clotting factor Xa and so reduces thrombin generation (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). Acenocoumarol is a coumarin derivative and a vitamin K antagonist. It reduces the gamma-carboxylation of clotting factors II, VII, IX and X, and its effect lasts a little over 24 hours (acenocoumarol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Edoxaban is contraindicated with any other anticoagulant, oral ones included, because of the increased risk of bleeding (EMA). Acenocoumarol is not named in this contraindication, but its own SmPC places it among the oral anticoagulants of the vitamin K antagonist group (AEMPS). Edoxaban itself prolongs the prothrombin time and the international normalised ratio (INR). With a vitamin K antagonist, it can raise the INR after an edoxaban dose by up to 46% (EMA).

Symptoms

Edoxaban increases the risk of bleeding, which can be severe or even fatal and can occur at any site (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). The most frequently reported adverse reactions with edoxaban are nosebleeds, blood in the urine and anaemia. Bleeding can present as weakness, pallor, dizziness, headache, unexplained swelling, shortness of breath or shock with no apparent cause (EMA). Acenocoumarol can also cause severe bleeding, up to haemorrhagic and hypovolaemic shock, or fatal bleeding. Concomitant treatment is one of the risk factors for such bleeding (acenocoumarol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). If haemoglobin or blood pressure falls without explanation, look for a bleeding site (EMA).

Management

Edoxaban is contraindicated with any other anticoagulant, oral ones included, except when switching from one oral anticoagulant to another (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). The US label does not recommend long-term use of edoxaban with other anticoagulants (edoxaban label, US Food and Drug Administration, ). The switching rules in the edoxaban SmPC cover vitamin K antagonists as a group. When switching from acenocoumarol, stop it and start edoxaban once the international normalised ratio (INR) is 2.5 or lower (EMA). When switching from edoxaban to acenocoumarol, keep anticoagulation continuous. With the oral option, patients on 60 mg take edoxaban 30 mg once daily together with a suitable dose of the vitamin K antagonist. Patients on 30 mg (creatinine clearance 15–50 mL/min, body weight 60 kg or less, or certain P-glycoprotein inhibitors) take 15 mg once daily (EMA). Do not give a loading dose of the vitamin K antagonist (EMA). The acenocoumarol SmPC also advises starting acenocoumarol without a loading dose (acenocoumarol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). During the first 14 days of co-administration, the edoxaban SmPC recommends measuring the INR at least three times, just before the daily edoxaban dose. Stop edoxaban once the INR reaches 2.0. After 14 days, the SmPC recommends stopping edoxaban and continuing to adjust the vitamin K antagonist dose to an INR of 2–3 (EMA). With the parenteral option, stop edoxaban and start a parenteral anticoagulant and the vitamin K antagonist at the time of the next scheduled edoxaban dose. Stop the parenteral anticoagulant once the INR is stable at 2.0 or higher (EMA). If severe bleeding occurs, stop edoxaban. There is no specific antidote, and vitamin K is not expected to affect edoxaban activity (EMA).

Pair details →Acenocoumarol →

CriticalApixabanDirect oral anticoagulants (factor Xa inhibitors)

Mechanism

Edoxaban and apixaban both directly and reversibly inhibit the same clotting factor, factor Xa, and reduce thrombin generation (edoxaban and apixaban summaries of product characteristics, SmPCs, European Medicines Agency, ). Both SmPCs contraindicate use with any other anticoagulant because of the increased risk of bleeding, and the edoxaban SmPC names apixaban (EMA). Healthy volunteers took apixaban for three days and switched to edoxaban on day 4. After the switch, their prothrombin time was the same as on day 3 of apixaban (edoxaban SmPC, EMA). This is why the first edoxaban dose after a switch can be given at the time of the next scheduled dose of the previous drug (EMA).

Symptoms

Edoxaban increases the risk of bleeding, which can be severe or even fatal and can occur at any site (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). The most frequently reported adverse reactions with edoxaban are nosebleeds, blood in the urine and anaemia. Bleeding can present as weakness, pallor, dizziness, headache, unexplained swelling, shortness of breath or shock with no apparent cause (EMA). If haemoglobin or blood pressure falls without explanation, look for a bleeding site. Standard coagulation tests are not suitable for monitoring the effect of edoxaban (EMA).

Management

Edoxaban is contraindicated with any other anticoagulant, except when switching from one oral anticoagulant to another. The edoxaban summary of product characteristics (SmPC) names apixaban in this contraindication (edoxaban SmPC, European Medicines Agency, ). The apixaban SmPC likewise contraindicates any other anticoagulant except in specific circumstances, including a switch of anticoagulant therapy (apixaban SmPC, EMA). When switching from apixaban to edoxaban, stop apixaban and start edoxaban at the time of the next scheduled apixaban dose (edoxaban SmPC, EMA). When switching from edoxaban to apixaban, stop edoxaban and start apixaban at the time of the next scheduled edoxaban dose (EMA). The US label does not recommend long-term use of edoxaban with other anticoagulants (edoxaban label, US Food and Drug Administration, ). Promptly evaluate any signs of blood loss (FDA). If severe bleeding occurs, stop edoxaban. There is no specific antidote (EMA).

Pair details →Apixaban →

CriticalDabigatranDirect thrombin inhibitor

Mechanism

Edoxaban directly and reversibly inhibits clotting factor Xa, and dabigatran directly and reversibly inhibits thrombin. Both drugs interfere with thrombus formation (edoxaban and dabigatran summaries of product characteristics, SmPCs, European Medicines Agency, ). Both SmPCs contraindicate use with any other anticoagulant, and the edoxaban SmPC names dabigatran (EMA). Healthy volunteers took dabigatran for three days and switched to edoxaban on day 4. Their activated partial thromboplastin time (aPTT) was higher than with edoxaban alone because of the residual effect of dabigatran. Bleeding time, however, was not prolonged (edoxaban SmPC, EMA). This is why the first edoxaban dose after a switch can be given at the time of the next scheduled dose of the previous drug (EMA).

Symptoms

Edoxaban increases the risk of bleeding, which can be severe or even fatal and can occur at any site (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). The most frequently reported adverse reactions with edoxaban are nosebleeds, blood in the urine and anaemia. Bleeding can present as weakness, pallor, dizziness, headache, unexplained swelling, shortness of breath or shock with no apparent cause (EMA). If haemoglobin or blood pressure falls without explanation, look for a bleeding site. Standard coagulation tests are not suitable for monitoring the effect of edoxaban (EMA). In the RE-LY study, other oral or parenteral anticoagulants raised major bleeding rates about 2.5-fold with both dabigatran and warfarin. This happened mainly when patients switched from one anticoagulant to another (dabigatran SmPC, EMA).

Management

Edoxaban is contraindicated with any other anticoagulant, except when switching from one oral anticoagulant to another. The edoxaban summary of product characteristics (SmPC) names dabigatran in this contraindication (edoxaban SmPC, European Medicines Agency, ). The dabigatran SmPC likewise contraindicates any other anticoagulant except in specific circumstances, including a switch of anticoagulant therapy (dabigatran SmPC, EMA). When switching from dabigatran to edoxaban, stop dabigatran and start edoxaban at the time of the next scheduled dabigatran dose (edoxaban SmPC, EMA). When switching from edoxaban to dabigatran, stop edoxaban and start dabigatran at the time of the next scheduled edoxaban dose (EMA). The US label does not recommend long-term use of edoxaban with other anticoagulants (edoxaban label, US Food and Drug Administration, ). Promptly evaluate any signs of blood loss (FDA). If severe bleeding occurs, stop edoxaban. There is no specific antidote (EMA).

Pair details →Dabigatran →

CriticalEnoxaparin sodiumLow-molecular-weight heparin (LMWH)

Mechanism

Edoxaban directly and reversibly inhibits clotting factor Xa and so reduces thrombin generation (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). Enoxaparin is a low molecular weight heparin. Through antithrombin III, it strongly inhibits factor Xa and, more weakly, thrombin (enoxaparin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Edoxaban is contraindicated with any other anticoagulant because of the increased risk of bleeding, and this contraindication names enoxaparin (EMA). The enoxaparin SmPC lists anticoagulants among the drugs affecting haemostasis whose concomitant use with enoxaparin is not recommended (AEMPS).

Symptoms

Edoxaban increases the risk of bleeding, which can be severe or even fatal and can occur at any site (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). The most frequently reported adverse reactions with edoxaban are nosebleeds, blood in the urine and anaemia. Bleeding can present as weakness, pallor, dizziness, headache, unexplained swelling, shortness of breath or shock with no apparent cause (EMA). Like any anticoagulant, enoxaparin can cause bleeding anywhere in the body. Neuraxial haematomas with prolonged or permanent paralysis have been reported in patients on enoxaparin who had spinal or epidural anaesthesia or lumbar puncture. The risk is higher with concomitant drugs that affect haemostasis (enoxaparin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).

Management

Edoxaban is contraindicated with low molecular weight heparins, enoxaparin included (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). The US label does not recommend long-term use of edoxaban with other anticoagulants (edoxaban label, US Food and Drug Administration, ). The switching exception in this contraindication covers oral anticoagulants. Do not give a parenteral anticoagulant and edoxaban at the same time, even during a switch (EMA). For deep vein thrombosis and pulmonary embolism, start edoxaban after at least 5 days of a parenteral anticoagulant, not together with it (EMA). When switching from enoxaparin, stop it and start edoxaban at the time of the next scheduled injection (EMA). The enoxaparin SmPC likewise says to stop enoxaparin when switching to a direct oral anticoagulant. Start the new drug 0–2 hours before the next scheduled injection, following its own SmPC (enoxaparin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). When switching from edoxaban to enoxaparin, stop edoxaban and give the first injection at the time of the next scheduled edoxaban dose. The enoxaparin SmPC says the same (EMA, AEMPS). If oral medicines cannot be taken during or after surgery, consider a parenteral anticoagulant and then switch to edoxaban (EMA). If severe bleeding occurs, stop edoxaban. There is no specific antidote, and protamine sulfate is not expected to affect edoxaban activity (EMA).

Pair details →Enoxaparin sodium →

CriticalRivaroxabanDirect oral anticoagulants (factor Xa inhibitors)

Mechanism

Edoxaban and rivaroxaban both directly inhibit the same clotting factor, factor Xa, and reduce thrombin generation (edoxaban and rivaroxaban summaries of product characteristics, SmPCs, European Medicines Agency, ). Both SmPCs contraindicate use with any other anticoagulant because of the increased risk of bleeding, and the edoxaban SmPC names rivaroxaban (EMA). Healthy volunteers took rivaroxaban for three days and switched to edoxaban on day 4. After the switch, their prothrombin time was the same as on day 3 of rivaroxaban (edoxaban SmPC, EMA). This is why the first edoxaban dose after a switch can be given at the time of the next scheduled dose of the previous drug (EMA).

Symptoms

Edoxaban increases the risk of bleeding, which can be severe or even fatal and can occur at any site (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). The most frequently reported adverse reactions with edoxaban are nosebleeds, blood in the urine and anaemia. Bleeding can present as weakness, pallor, dizziness, headache, unexplained swelling, shortness of breath or shock with no apparent cause (EMA). If haemoglobin or blood pressure falls without explanation, look for a bleeding site. Standard coagulation tests are not suitable for monitoring the effect of edoxaban (EMA).

Management

Edoxaban is contraindicated with any other anticoagulant, except when switching from one oral anticoagulant to another. The edoxaban summary of product characteristics (SmPC) names rivaroxaban in this contraindication (edoxaban SmPC, European Medicines Agency, ). The rivaroxaban SmPC likewise contraindicates any other anticoagulant except in specific circumstances, including a switch of anticoagulant therapy (rivaroxaban SmPC, EMA). When switching from rivaroxaban to edoxaban, stop rivaroxaban and start edoxaban at the time of the next scheduled rivaroxaban dose (edoxaban SmPC, EMA). When switching from edoxaban to rivaroxaban, stop edoxaban and start rivaroxaban at the time of the next scheduled edoxaban dose (EMA). The US edoxaban label does not recommend long-term use of edoxaban with other anticoagulants (edoxaban label, US Food and Drug Administration, ). The US rivaroxaban label says to avoid other anticoagulants with rivaroxaban unless the benefit outweighs the risk (rivaroxaban label, FDA). Promptly evaluate any signs of blood loss (edoxaban label, FDA). If severe bleeding occurs, stop edoxaban. There is no specific antidote (EMA).

Pair details →Rivaroxaban →

CriticalValproic acidAntiepileptics. Fatty acid derivatives

Mechanism

The antiepileptic drug table of the European Heart Rhythm Association (EHRA) practical guide gives induction or inhibition of the CYP3A4 enzyme and the efflux transporter P-glycoprotein (P-gp) as the interaction route for valproic acid. The same table lists edoxaban as a P-gp substrate, with "No (<4%)" in the CYP3A4 substrate row (EHRA 2021). The guide's text says that valproate may have unpredictable effects on CYP3A4 and that, in animal and/or human studies, valproic acid may decrease the effect of direct oral anticoagulants by inducing P-gp activity (EHRA 2021). The valproate labels put it differently: the Spanish SmPC says valproate has no enzyme-inducing effect (valproate summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS), and the US label calls it a weak inhibitor of some cytochrome P450 isozymes (valproate label, US Food and Drug Administration, ). A second mechanism does not depend on edoxaban levels: valproate causes dose-related thrombocytopenia, inhibits the secondary phase of platelet aggregation and may cause abnormal coagulation parameters (valproate label, FDA), and the Spanish SmPC says that use with anticoagulants may increase the bleeding tendency (valproate SmPC, AEMPS).

Symptoms

According to the EHRA table legend, valproic acid lowers edoxaban levels, which carries a risk of thrombosis: stroke or systemic embolism in atrial fibrillation, and recurrent deep vein thrombosis or pulmonary embolism in venous thromboembolism (EHRA 2021). Valproate itself commonly causes thrombocytopenia and bleeding (valproate SmPC, AEMPS). Signs include bruising, red or purple spots on the skin, bleeding from the nose or mouth, vomiting blood or material that looks like coffee grounds, and blood in the stools or black stools (valproate label, ). A retrospective cohort from Taiwan found bleeding more often when direct oral anticoagulants and valproic acid were prescribed together, but the authors note that this result may not apply to other patient groups (EHRA 2021).

Management

The combination is contraindicated in the practical guide of the European Heart Rhythm Association (EHRA): its antiepileptic drug table marks the edoxaban and valproic acid cell as contraindicated because of reduced anticoagulant levels (EHRA 2021). If antiepileptic treatment cannot be avoided in a person with atrial fibrillation who takes a direct oral anticoagulant, the guide calls for vigilance for drug interactions and regular joint review by the cardiologist, neurologist, primary care physician and clinical pharmacist (EHRA 2021). Anticoagulant plasma level measurements are often proposed in this setting, but there is no outcome trial evidence for dosing by measured levels, so the authors advise treating such patients at expert centres with experience in these measurements and their interpretation (EHRA 2021). Check a full blood count with platelets, bleeding time and coagulation tests before starting valproate, before surgery and in case of spontaneous bruising or bleeding (valproate summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). With anticoagulants, the same SmPC recommends regular monitoring of blood coagulation (valproate SmPC, AEMPS). The US label recommends blood counts and coagulation tests before starting valproate and at periodic intervals, and states that haemorrhage, bruising or a disorder of haemostasis is an indication to reduce the valproate dose or stop it (valproate label, US Food and Drug Administration, ). If valproate is started in a person who already takes an anticoagulant, monitor coagulation tests (valproate label, FDA). The protein-binding data in that section of the US label come from warfarin (valproate label, FDA).

Pair details →Valproic acid →

CriticalWarfarinVitamin K antagonist anticoagulants

Mechanism

Edoxaban directly and reversibly inhibits clotting factor Xa and so reduces thrombin generation (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). Warfarin prevents the liver from forming active clotting factors II, VII, IX and X by inhibiting the vitamin K-mediated gamma-carboxylation of their precursor proteins (warfarin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Edoxaban is contraindicated with any other anticoagulant because of the increased risk of bleeding, and this contraindication names warfarin (EMA). Edoxaban itself prolongs the prothrombin time and the international normalised ratio (INR). With a vitamin K antagonist, it can raise the INR after an edoxaban dose by up to 46% (EMA).

Symptoms

Edoxaban increases the risk of bleeding, which can be severe or even fatal and can occur at any site (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). The most frequently reported adverse reactions with edoxaban are nosebleeds, blood in the urine and anaemia. Bleeding can present as weakness, pallor, dizziness, headache, unexplained swelling, shortness of breath or shock with no apparent cause (EMA). If haemoglobin or blood pressure falls without explanation, look for a bleeding site (EMA). With warfarin, too, the most serious risk is bleeding in any tissue or organ (warfarin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).

Management

Edoxaban is contraindicated with any other anticoagulant, including warfarin, except when switching from one oral anticoagulant to another (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). The US label does not recommend long-term use of edoxaban with other anticoagulants (edoxaban label, US Food and Drug Administration, ). When switching from warfarin to edoxaban, stop warfarin and start edoxaban once the international normalised ratio (INR) is 2.5 or lower (EMA). When switching from edoxaban to warfarin, keep anticoagulation continuous. With the oral option, patients on 60 mg take edoxaban 30 mg once daily together with a suitable warfarin dose. Patients on 30 mg (creatinine clearance 15–50 mL/min, body weight 60 kg or less, or certain P-glycoprotein inhibitors) take 15 mg once daily. Do not give a warfarin loading dose (EMA). During the first 14 days of co-administration, the edoxaban SmPC recommends measuring the INR at least three times, just before the daily edoxaban dose. Stop edoxaban once the INR reaches 2.0. After 14 days, the SmPC recommends stopping edoxaban and continuing to adjust the warfarin dose to an INR of 2–3 (EMA). With the parenteral option, stop edoxaban and start a parenteral anticoagulant and warfarin at the time of the next scheduled edoxaban dose. Stop the parenteral anticoagulant once the INR is stable at 2.0 or higher (EMA). Measure the INR more often whenever other medicines are started, stopped or taken irregularly. Monitor coagulation closely when any drug is added to or withdrawn from a coumarin anticoagulant (warfarin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). If severe bleeding occurs, stop edoxaban. There is no specific antidote, and vitamin K is not expected to affect edoxaban activity (EMA).

Pair details →Warfarin →

MajorAcetylsalicylic acidAntiplatelet agents (low dose) / NSAIDs (analgesic dose)

Mechanism

Edoxaban directly and reversibly inhibits coagulation factor Xa (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). Acetylsalicylic acid irreversibly inhibits platelet aggregation by blocking platelet cyclooxygenase (acetylsalicylic acid SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Acetylsalicylic acid 100 mg or 325 mg given with edoxaban prolonged bleeding time more than either drug alone (EMA). High-dose acetylsalicylic acid (325 mg) raised steady-state edoxaban Cmax by 35% and AUC by 32%. A low dose of 100 mg or less did not change edoxaban exposure (EMA). In edoxaban clinical studies, major bleeding was roughly twice as frequent with concomitant low-dose acetylsalicylic acid, other antiplatelets and thienopyridines. Even so, major bleeding was about as frequent with edoxaban as with warfarin (EMA).

Symptoms

The risk of bleeding rises. Bleeding can occur at any site and may be severe or even fatal (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). The most frequently reported adverse reactions with edoxaban are nosebleeds, blood in the urine and anaemia. Common adverse reactions also include gastrointestinal bleeding, bleeding in the mouth and throat, bleeding into the skin and soft tissues, and vaginal bleeding (EMA). Bleeding complications may present as weakness, pallor, dizziness, headache, unexplained swelling, shortness of breath or shock with no apparent cause (EMA). With acetylsalicylic acid, black stools, vomiting blood, a drop in blood pressure, cold sweat, abdominal pain and dizziness may signal bleeding, especially from the upper gastrointestinal tract (acetylsalicylic acid SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).

Management

The combination is not contraindicated, but whenever possible, avoid combining acetylsalicylic acid with anticoagulants, edoxaban included. If the combination is judged necessary, use it with caution and warn the patient about the signs of bleeding (acetylsalicylic acid summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). If the combination cannot be avoided, the same SmPC calls for careful monitoring of the INR, the international normalised ratio (AEMPS). The edoxaban SmPC, however, says that standard laboratory tests cannot reliably monitor the anticoagulant effect of edoxaban (edoxaban SmPC, European Medicines Agency, ). Low-dose acetylsalicylic acid, up to 100 mg a day, can be taken with edoxaban. Give doses above 100 mg only under medical supervision. The edoxaban SmPC does not recommend long-term high-dose acetylsalicylic acid (325 mg) with edoxaban (EMA). In older patients, combine edoxaban and acetylsalicylic acid with caution because of a potentially higher risk of bleeding (EMA). If haemoglobin or blood pressure falls without explanation, look for a bleeding site, and stop edoxaban if severe bleeding occurs (EMA). According to the US edoxaban label, monitor patients who need long-term low-dose acetylsalicylic acid carefully for bleeding (edoxaban prescribing information, US Food and Drug Administration, ).

Pair details →Acetylsalicylic acid →

MajorCarbamazepineAntiepileptics. Carboxamide derivatives

Mechanism

Edoxaban is a substrate of P-glycoprotein (P-gp), an efflux transporter. Carbamazepine is one of the P-gp inducers that may lower edoxaban plasma levels (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). Carbamazepine may reduce plasma levels of direct oral anticoagulants, edoxaban included, which carries a risk of thrombosis (carbamazepine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The resulting anticoagulant levels may be too low for the intended effect (carbamazepine label, US Food and Drug Administration, ). Neither the labels nor the European Heart Rhythm Association table says how much edoxaban levels fall (EHRA 2021).

Symptoms

The main risk is thrombosis because edoxaban works less well (carbamazepine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). In atrial fibrillation, this means ischaemic stroke or systemic embolism, and in venous thromboembolism a recurrence of deep vein thrombosis or pulmonary embolism. Signs include leg swelling and pain, sudden shortness of breath and chest pain, sudden weakness or numbness of an arm, a leg or one side of the face, and difficulty speaking.

Management

In general, avoid combining carbamazepine with edoxaban, as with rivaroxaban, apixaban and dabigatran (carbamazepine label, US Food and Drug Administration, ). If the combination cannot be avoided, monitor closely for signs and symptoms of thrombosis (carbamazepine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Use caution when edoxaban is combined with P-glycoprotein (P-gp) inducers, carbamazepine included (edoxaban SmPC, European Medicines Agency, ). The European Heart Rhythm Association table also requires caution for this pair, especially with polypharmacy or with two or more interactions that lower anticoagulant levels (EHRA 2021). The Spanish carbamazepine SmPC lists oral anticoagulants, edoxaban included, among the drugs whose doses are adjusted to clinical need (AEMPS). The dosing section of the edoxaban SmPC, however, lists only reasons to reduce the dose to 30 mg. It gives no specific dose for use with inducers (edoxaban SmPC, EMA). If edoxaban is stopped because of carbamazepine, keep anticoagulation continuous and switch to another anticoagulant as the edoxaban SmPC describes (EMA). With carbamazepine, the doses of warfarin and acenocoumarol are also adjusted to clinical need (carbamazepine SmPC, AEMPS).

Pair details →Carbamazepine →

MajorCiclosporinImmunosuppressants. Calcineurin inhibitors

Mechanism

Edoxaban is a substrate of the efflux transporter P-glycoprotein (P-gp). Ciclosporin inhibits this transporter, so edoxaban plasma levels rise (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ; ciclosporin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Single doses of ciclosporin 500 mg and edoxaban 60 mg taken together increased the edoxaban area under the concentration–time curve (AUC) by 73% and its peak concentration by 74% (edoxaban SmPC, EMA). The kidneys account for about half of total edoxaban clearance (edoxaban SmPC, EMA), and ciclosporin often raises serum creatinine and urea (ciclosporin SmPC, AEMPS). People taking ciclosporin were excluded from the main edoxaban trials, so the combination has not been studied in patients (edoxaban label, US Food and Drug Administration, ).

Symptoms

The main risk is bleeding. It can occur at any site and can be severe or even fatal (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). The most frequently reported adverse reactions with edoxaban are nosebleeds, blood in the urine and anaemia. Gastrointestinal bleeding, vaginal bleeding and bleeding into the skin are common. Intracranial bleeding is uncommon, and menstrual bleeding may become heavier or last longer (edoxaban SmPC, EMA). Bleeding can present as weakness, pallor, dizziness, headache, unexplained swelling, shortness of breath or shock with no apparent cause. An unexplained fall in haemoglobin or blood pressure points to hidden bleeding (edoxaban SmPC, EMA).

Management

With ciclosporin, the recommended edoxaban dose is 30 mg once daily instead of the usual 60 mg. This applies both in atrial fibrillation and in deep vein thrombosis and pulmonary embolism (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). The European Heart Rhythm Association table gives the same dose for this pair (EHRA 2021). Several reasons for reduction do not lower the dose further. With creatinine clearance of 15–50 mL/min or body weight of 60 kg or less as well, it stays at 30 mg (edoxaban SmPC, EMA). The ciclosporin SmPC contraindicates combinations with P-glycoprotein (P-gp) substrates whose high plasma levels are linked to serious or life-threatening adverse reactions. Its examples are bosentan, dabigatran and aliskiren, and edoxaban is not among them (ciclosporin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Check kidney function often, because ciclosporin can impair it (ciclosporin SmPC, AEMPS). To set the edoxaban dose, calculate creatinine clearance with the Cockcroft–Gault formula before treatment. Calculate it again whenever kidney function may have changed, including because of other medicines (edoxaban SmPC, EMA). Edoxaban is not recommended in patients with creatinine clearance below 15 mL/min or on dialysis (edoxaban SmPC, EMA). Promptly evaluate any signs of blood loss (edoxaban label, US Food and Drug Administration, ). Haemoglobin and haematocrit may help detect hidden bleeding. Stop edoxaban if severe bleeding occurs (edoxaban SmPC, EMA). There is no specific antidote, and haemodialysis removes little edoxaban. For life-threatening bleeding that cannot be controlled, the SmPC describes a 4-factor prothrombin complex concentrate at 50 IU/kg. It reversed the effects of edoxaban 30 minutes after the end of the infusion (edoxaban SmPC, EMA). In the USA, the edoxaban dose for atrial fibrillation is not reduced because of P-gp inhibitors. The US label also states that edoxaban has not been studied with ciclosporin in patients (edoxaban label, FDA).

Pair details →Ciclosporin →

MajorClopidogrelAntiplatelet agents – P2Y12 receptor inhibitors

Mechanism

Edoxaban directly and reversibly inhibits coagulation factor Xa (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). The active metabolite of clopidogrel irreversibly blocks the platelet P2Y12 receptor. Platelets exposed to it stay affected for the rest of their lifespan, about 7–10 days (clopidogrel SmPC, EMA). According to the clopidogrel SmPC, combining clopidogrel with oral anticoagulants may make bleeding more severe (EMA). In the ENGAGE AF-TIMI 48 study in non-valvular atrial fibrillation, patients taking edoxaban were allowed thienopyridine monotherapy, such as clopidogrel. Clinically relevant bleeding increased, although the risk of bleeding was lower with edoxaban than with warfarin (edoxaban SmPC, EMA).

Symptoms

The risk of bleeding rises. Bleeding can occur at any site and may be severe or even fatal (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). The most frequently reported adverse reactions with edoxaban are nosebleeds, blood in the urine and anaemia. Common adverse reactions also include gastrointestinal bleeding, bleeding in the mouth and throat, bleeding into the skin and soft tissues, and vaginal bleeding (EMA). Bleeding complications may present as weakness, pallor, dizziness, headache, unexplained swelling, shortness of breath or shock with no apparent cause (EMA). In people taking clopidogrel, bleeding may last longer than usual (clopidogrel SmPC, EMA).

Management

The combination is not contraindicated. The clopidogrel summary of product characteristics (SmPC), however, does not recommend combining clopidogrel with oral anticoagulants, edoxaban included, because bleeding may become more severe (clopidogrel SmPC, European Medicines Agency, ). Experience with edoxaban and dual antiplatelet therapy is very limited (edoxaban SmPC, EMA). Monitor patients taking clopidogrel closely for any sign of bleeding, including hidden bleeding, especially in the first weeks of treatment and after surgery. If symptoms suggest bleeding, promptly decide whether a full blood count and other tests are needed (clopidogrel SmPC, EMA). If haemoglobin or blood pressure falls without explanation, look for a bleeding site, and stop edoxaban if severe bleeding occurs (edoxaban SmPC, EMA). Before elective surgery, if an antiplatelet effect is not needed, stop clopidogrel 7 days in advance (clopidogrel SmPC, EMA). If anticoagulation has to be interrupted, stop edoxaban as early as possible, preferably at least 24 hours before the procedure (edoxaban SmPC, EMA). According to the US edoxaban label, promptly evaluate any sign or symptom of blood loss in patients who also take other platelet aggregation inhibitors (edoxaban prescribing information, US Food and Drug Administration, ).

Pair details →Clopidogrel →

MajorDiclofenacNon-steroidal anti-inflammatory drugs (NSAIDs)

Mechanism

Edoxaban blocks clotting factor Xa (edoxaban SmPC, ). Diclofenac, like other non-steroidal anti-inflammatory drugs (NSAIDs), can temporarily inhibit platelet aggregation and cause ulcers and bleeding in the stomach and gut (diclofenac summary of product characteristics, SmPC). According to clinical studies, diclofenac does not seem to change the action of anticoagulants. There are, however, reports of more frequent bleeding when the two are combined (diclofenac SmPC). In clinical studies, NSAIDs given with edoxaban increased clinically relevant bleeding (edoxaban SmPC, European Medicines Agency, EMA). Among NSAIDs, pharmacokinetic data with edoxaban exist only for naproxen, which did not change edoxaban levels (edoxaban SmPC, EMA).

Symptoms

The most frequently reported adverse reactions with edoxaban are nosebleeds, blood in the urine and anaemia. Bleeding can occur at any site and can be severe (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). Diclofenac adds a risk of ulcers and gastrointestinal bleeding, especially in older people, in people with a previous ulcer and at higher doses (diclofenac SmPC). Such bleeding presents as black, tarry stools (melaena), vomiting of blood or coffee-ground material, and abdominal pain. An unexplained fall in haemoglobin or blood pressure can point to hidden bleeding (edoxaban SmPC, EMA).

Management

The edoxaban summary of product characteristics (SmPC) does not recommend long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) with edoxaban (edoxaban SmPC, European Medicines Agency, ). Give diclofenac at the lowest effective dose for the shortest time. Use it with caution together with anticoagulants and monitor the patient closely (diclofenac SmPC). If long-term NSAID treatment cannot be avoided, monitor carefully for bleeding and promptly evaluate any sign of blood loss (edoxaban prescribing information, US Food and Drug Administration, ). Diclofenac is contraindicated in established congestive heart failure (New York Heart Association, NYHA, class II–IV), ischaemic heart disease, peripheral arterial disease and cerebrovascular disease (diclofenac SmPC). In older patients and in those with a previous ulcer, start diclofenac at the lowest effective dose and give it with gastroprotection (misoprostol or a proton pump inhibitor). Consider the same protection when other drugs raise the risk of gastrointestinal bleeding (diclofenac SmPC). Check creatinine clearance before starting edoxaban and later when clinically indicated (edoxaban SmPC, EMA). Diclofenac is contraindicated in severe renal impairment. In mild to moderate impairment, use it with caution (diclofenac SmPC). Edoxaban is contraindicated in a lesion or condition that carries a significant risk of major bleeding, such as an active or recent gastrointestinal ulcer (edoxaban SmPC, EMA). Diclofenac is contraindicated in active ulcer, bleeding or perforation and after previous NSAID-related bleeding or perforation (diclofenac SmPC). Stop diclofenac at once if gastrointestinal bleeding or an ulcer occurs (diclofenac SmPC). In severe bleeding, interrupt edoxaban as well (edoxaban SmPC, EMA).

Pair details →Diclofenac →

MajorDronedaroneClass III antiarrhythmic

Mechanism

Dronedarone strongly inhibits the transporter P-glycoprotein (P-gp) and moderately inhibits the enzyme CYP3A4 (dronedarone summary of product characteristics, SmPC, European Medicines Agency, ). Edoxaban is a P-gp substrate, and CYP3A4/5 accounts for less than 10% of its metabolism (edoxaban SmPC, EMA). Dronedarone 400 mg twice daily for 7 days increased the edoxaban area under the concentration–time curve (AUC) by 85% and its peak concentration by 46% (edoxaban SmPC, EMA). Dronedarone itself raises serum creatinine by 10 µmol/L on average, usually early in treatment, with a plateau after 7 days (dronedarone SmPC, EMA). The edoxaban dose depends on creatinine clearance (edoxaban SmPC, EMA).

Symptoms

The main risk is bleeding. It can occur at any site and can be severe or even fatal (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). The most frequently reported adverse reactions with edoxaban are nosebleeds, blood in the urine and anaemia. Gastrointestinal bleeding, vaginal bleeding and bleeding into the skin are common. Intracranial bleeding is uncommon, and menstrual bleeding may become heavier or last longer (edoxaban SmPC, EMA). Bleeding can present as weakness, pallor, dizziness, headache, unexplained swelling, shortness of breath or shock with no apparent cause. An unexplained fall in haemoglobin or blood pressure points to hidden bleeding (edoxaban SmPC, EMA).

Management

With dronedarone, the recommended edoxaban dose is 30 mg once daily instead of the usual 60 mg (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). The dronedarone SmPC also says to reduce the edoxaban dose according to the edoxaban product information (dronedarone SmPC, EMA). The European Heart Rhythm Association table gives the same 30 mg dose (EHRA 2021). Several reasons for reduction do not lower the dose further. With creatinine clearance of 15–50 mL/min or body weight of 60 kg or less as well, it stays at 30 mg (edoxaban SmPC, EMA). Dronedarone is contraindicated when creatinine clearance is below 30 mL/min (dronedarone SmPC, EMA). Measure creatinine before starting dronedarone and after 7 days. If it has risen, measure it again after another 7 days. If there is no further rise, use this value as the new baseline, and then check kidney function regularly (dronedarone SmPC, EMA). During dronedarone treatment, monitor co-administered anticoagulants (dronedarone SmPC, EMA). Promptly evaluate any signs of blood loss (edoxaban label, US Food and Drug Administration, ), and stop edoxaban if severe bleeding occurs (edoxaban SmPC, EMA). There is no specific antidote. For life-threatening bleeding that cannot be controlled, the SmPC describes a 4-factor prothrombin complex concentrate at 50 IU/kg. It reversed the effects of edoxaban 30 minutes after the end of the infusion (edoxaban SmPC, EMA). In the USA, the edoxaban dose for atrial fibrillation is not reduced because of P-glycoprotein (P-gp) inhibitors. In the ENGAGE AF-TIMI 48 trial, patients taking these inhibitors who received the reduced dose had lower edoxaban levels than patients given the full dose (edoxaban label, FDA).

Pair details →Dronedarone →

MajorErythromycinMacrolide antibiotic

Mechanism

Erythromycin moderately inhibits the transporter P-glycoprotein (P-gp) and the enzyme CYP3A4 (erythromycin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Edoxaban is a P-gp substrate (edoxaban SmPC, European Medicines Agency, ). Erythromycin 500 mg four times daily for 8 days increased the edoxaban area under the concentration–time curve (AUC) by 85% and its peak concentration by 68% (edoxaban SmPC, EMA). The Spanish erythromycin SmPCs report a stronger effect of oral anticoagulants, such as warfarin and rivaroxaban, taken with erythromycin (erythromycin SmPC, AEMPS). According to the erythromycin label of the US Food and Drug Administration (), this effect may be more pronounced in older people.

Symptoms

The main risk is bleeding. It can occur at any site and can be severe or even fatal (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). The most frequently reported adverse reactions with edoxaban are nosebleeds, blood in the urine and anaemia. Gastrointestinal bleeding, vaginal bleeding and bleeding into the skin are common. Intracranial bleeding is uncommon, and menstrual bleeding may become heavier or last longer (edoxaban SmPC, EMA). Bleeding can present as weakness, pallor, dizziness, headache, unexplained swelling, shortness of breath or shock with no apparent cause. An unexplained fall in haemoglobin or blood pressure points to hidden bleeding (edoxaban SmPC, EMA).

Management

With erythromycin, the recommended edoxaban dose is 30 mg once daily instead of the usual 60 mg (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). The European Heart Rhythm Association table gives the same dose for this pair (EHRA 2021). Several reasons for reduction do not lower the dose further. With creatinine clearance of 15–50 mL/min or body weight of 60 kg or less as well, it stays at 30 mg (edoxaban SmPC, EMA). In the edoxaban SmPC, the 30 mg dose applies while the two drugs are taken together. The US label describes the edoxaban trial in deep vein thrombosis and pulmonary embolism. There, patients took 30 mg during a short course of erythromycin. They went back to 60 mg as soon as they stopped erythromycin, unless there was another reason for a lower dose (edoxaban label, US Food and Drug Administration, ). Oral anticoagulants may act more strongly with erythromycin (erythromycin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS), especially in older people (erythromycin label, FDA). Promptly evaluate any signs of blood loss (edoxaban label, FDA). Haemoglobin and haematocrit may help detect hidden bleeding. Stop edoxaban if severe bleeding occurs (edoxaban SmPC, EMA). There is no specific antidote. For life-threatening bleeding that cannot be controlled, the SmPC describes a 4-factor prothrombin complex concentrate at 50 IU/kg. It reversed the effects of edoxaban 30 minutes after the end of the infusion (edoxaban SmPC, EMA). In the USA, the edoxaban dose for atrial fibrillation is not reduced because of P-glycoprotein (P-gp) inhibitors (edoxaban label, FDA).

Pair details →Erythromycin →

MajorIbuprofenNon-steroidal anti-inflammatory drugs (NSAIDs)

Mechanism

Edoxaban blocks clotting factor Xa (edoxaban SmPC, ). Ibuprofen, like other non-steroidal anti-inflammatory drugs (NSAIDs), can reduce platelet aggregation, prolong bleeding time and cause ulcers and bleeding in the stomach and gut (ibuprofen summary of product characteristics, SmPC). Bleeding time can stay prolonged for up to a day after ibuprofen is stopped (ibuprofen SmPC). In clinical studies, NSAIDs given with edoxaban increased clinically relevant bleeding (edoxaban SmPC, European Medicines Agency, EMA). Among NSAIDs, pharmacokinetic data with edoxaban exist only for naproxen, which did not change edoxaban levels (edoxaban SmPC, EMA).

Symptoms

The most frequently reported adverse reactions with edoxaban are nosebleeds, blood in the urine and anaemia. Bleeding can occur at any site and can be severe (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). Ibuprofen adds a risk of ulcers and gastrointestinal bleeding, especially in older people, in people with a previous ulcer and at higher doses (ibuprofen SmPC). Such bleeding presents as black, tarry stools (melaena), vomiting of blood or coffee-ground material, and abdominal pain. An unexplained fall in haemoglobin or blood pressure can point to hidden bleeding (edoxaban SmPC, EMA).

Management

The edoxaban summary of product characteristics (SmPC) does not recommend long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) with edoxaban (edoxaban SmPC, European Medicines Agency, ). Give ibuprofen at the lowest effective dose for the shortest time. Use NSAIDs with caution together with drugs that raise the risk of gastrointestinal bleeding (ibuprofen SmPC). If long-term NSAID treatment cannot be avoided, monitor carefully for bleeding and promptly evaluate any sign of blood loss (edoxaban prescribing information, US Food and Drug Administration, ). During long-term ibuprofen treatment, check kidney and liver function, haematological parameters and blood counts (ibuprofen SmPC). In older patients and in those with a previous ulcer, start ibuprofen at the lowest dose and give it with gastroprotection (misoprostol or a proton pump inhibitor). Consider the same protection when other drugs raise the risk of gastrointestinal bleeding (ibuprofen SmPC). Check creatinine clearance before starting edoxaban and later when clinically indicated (edoxaban SmPC, EMA). In kidney disease, keep the ibuprofen dose as low as possible and check kidney function regularly (ibuprofen SmPC). Edoxaban is contraindicated in a lesion or condition that carries a significant risk of major bleeding, such as an active or recent gastrointestinal ulcer (edoxaban SmPC, EMA). Stop ibuprofen at once if gastrointestinal bleeding or an ulcer occurs (ibuprofen SmPC). In severe bleeding, interrupt edoxaban as well (edoxaban SmPC, EMA).

Pair details →Ibuprofen →

MajorKetoconazoleSystemic antimycotics. Imidazole derivatives

Mechanism

Ketoconazole strongly inhibits the transporter P-glycoprotein (P-gp) and the enzyme CYP3A4 (ketoconazole summary of product characteristics, SmPC, European Medicines Agency, ). Edoxaban is a P-gp substrate (edoxaban SmPC, EMA). Ketoconazole 400 mg once daily for 7 days increased the edoxaban area under the concentration–time curve (AUC) by 87% and its peak concentration by 89% (edoxaban SmPC, EMA). According to the ketoconazole SmPC, both values rose 1.8-fold (ketoconazole SmPC, EMA). In the EU, ketoconazole tablets are indicated for endogenous Cushing's syndrome in adults and adolescents over 12 years (ketoconazole SmPC, EMA). After ketoconazole cream was applied to the skin of adults, no measurable ketoconazole levels were found in plasma (ketoconazole cream SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).

Symptoms

The main risk is bleeding. It can occur at any site and can be severe or even fatal (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). The most frequently reported adverse reactions with edoxaban are nosebleeds, blood in the urine and anaemia. Gastrointestinal bleeding, vaginal bleeding and bleeding into the skin are common. Intracranial bleeding is uncommon, and menstrual bleeding may become heavier or last longer (edoxaban SmPC, EMA). Bleeding can present as weakness, pallor, dizziness, headache, unexplained swelling, shortness of breath or shock with no apparent cause. An unexplained fall in haemoglobin or blood pressure points to hidden bleeding (edoxaban SmPC, EMA).

Management

With oral ketoconazole, the recommended edoxaban dose is 30 mg once daily instead of the usual 60 mg (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). The ketoconazole SmPC also says to reduce the edoxaban dose during combined use according to the edoxaban SmPC (ketoconazole SmPC, EMA). The European Heart Rhythm Association table gives the same 30 mg dose (EHRA 2021). Several reasons for reduction do not lower the dose further. With creatinine clearance of 15–50 mL/min or body weight of 60 kg or less as well, it stays at 30 mg (edoxaban SmPC, EMA). Ketoconazole can damage the liver. Do not start it if liver enzymes are more than twice the upper limit of normal. Check liver enzymes and bilirubin before treatment, weekly for the first month and then monthly for 6 months (ketoconazole SmPC, EMA). Edoxaban is contraindicated in liver disease with coagulopathy and a clinically relevant bleeding risk (edoxaban SmPC, EMA). Promptly evaluate any signs of blood loss (edoxaban label, US Food and Drug Administration, ). Haemoglobin and haematocrit may help detect hidden bleeding. Stop edoxaban if severe bleeding occurs (edoxaban SmPC, EMA). There is no specific antidote. For life-threatening bleeding that cannot be controlled, the SmPC describes a 4-factor prothrombin complex concentrate at 50 IU/kg. It reversed the effects of edoxaban 30 minutes after the end of the infusion (edoxaban SmPC, EMA). In the USA, the edoxaban dose for atrial fibrillation is not reduced because of P-glycoprotein (P-gp) inhibitors. In deep vein thrombosis and pulmonary embolism, the dose is reduced to 30 mg with certain P-gp inhibitors. In the trial, these included a short course of oral ketoconazole (edoxaban label, FDA).

Pair details →Ketoconazole →

MajorKetoprofenNon-steroidal anti-inflammatory drug, propionic acid derivative

Mechanism

Edoxaban blocks clotting factor Xa (edoxaban SmPC, ). Non-selective non-steroidal anti-inflammatory drugs (NSAIDs), ketoprofen among them, inhibit prostaglandin synthesis and can therefore reduce platelet aggregation and prolong bleeding time (ketoprofen summary of product characteristics, SmPC). Ketoprofen can cause ulcers and bleeding in the stomach and gut. Epidemiological data suggest that its risk of serious gastrointestinal complications may be higher than with other NSAIDs, especially at high doses (ketoprofen SmPC). In clinical studies, NSAIDs given with edoxaban increased clinically relevant bleeding (edoxaban SmPC, European Medicines Agency, EMA). Among NSAIDs, pharmacokinetic data with edoxaban exist only for naproxen, which did not change edoxaban levels (edoxaban SmPC, EMA).

Symptoms

The most frequently reported adverse reactions with edoxaban are nosebleeds, blood in the urine and anaemia. Bleeding can occur at any site and can be severe (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). Ketoprofen adds a risk of ulcers and gastrointestinal bleeding, especially in older people, in people with a previous ulcer and at higher doses (ketoprofen SmPC). Such bleeding presents as black, tarry stools (melaena), vomiting of blood or coffee-ground material, and abdominal pain. An unexplained fall in haemoglobin or blood pressure can point to hidden bleeding (edoxaban SmPC, EMA).

Management

The ketoprofen summary of product characteristics (SmPC) does not recommend ketoprofen with direct factor Xa inhibitors, edoxaban included. This advice does not depend on how long the drugs are taken (ketoprofen SmPC). The edoxaban SmPC also does not recommend long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) with edoxaban (edoxaban SmPC, European Medicines Agency, ). If the combination cannot be avoided, monitor the patient strictly, both clinically and with laboratory tests (ketoprofen SmPC). Monitor carefully for bleeding and promptly evaluate any sign of blood loss (edoxaban prescribing information, US Food and Drug Administration, ). Give ketoprofen at the lowest effective dose for the shortest time (ketoprofen SmPC). In older patients and in those with a previous ulcer, start ketoprofen at the lowest dose. Give gastroprotection (misoprostol or a proton pump inhibitor) to them and to patients taking other drugs that raise the risk of gastrointestinal complications (ketoprofen SmPC). Ketoprofen is contraindicated in moderate to severe renal impairment (ketoprofen SmPC). Check creatinine clearance before starting edoxaban and later when clinically indicated (edoxaban SmPC, EMA). Edoxaban is contraindicated in a lesion or condition that carries a significant risk of major bleeding, such as an active or recent gastrointestinal ulcer (edoxaban SmPC, EMA). Ketoprofen is contraindicated in active peptic ulcer and after previous gastrointestinal bleeding, ulcer or perforation (ketoprofen SmPC). Stop ketoprofen at once if gastrointestinal bleeding or an ulcer occurs (ketoprofen SmPC). In severe bleeding, interrupt edoxaban as well (edoxaban SmPC, EMA).

Pair details →Ketoprofen →

MajorNaproxenNSAID, propionic acid derivative

Mechanism

Edoxaban blocks clotting factor Xa (edoxaban SmPC, ), while naproxen reduces platelet aggregation, prolongs bleeding time and can cause ulcers and bleeding in the stomach and gut (naproxen summary of product characteristics, SmPC). Taken together, they prolonged bleeding time more than either drug alone (edoxaban SmPC, European Medicines Agency, EMA). In clinical studies, non-steroidal anti-inflammatory drugs (NSAIDs) given with edoxaban increased clinically relevant bleeding. Naproxen did not change the area under the concentration curve (AUC) or the peak concentration of edoxaban (edoxaban SmPC, EMA). The risk of this pair therefore comes from added effects on clotting and the gut lining, not from higher edoxaban levels.

Symptoms

The most frequently reported adverse reactions with edoxaban are nosebleeds, blood in the urine and anaemia. Bleeding can occur at any site and can be severe (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). Naproxen adds a risk of ulcers and gastrointestinal bleeding, especially in older people, in people with a previous ulcer and at higher doses (naproxen SmPC). Such bleeding presents as black, tarry stools (melaena), vomiting of blood or coffee-ground material, and abdominal pain. An unexplained fall in haemoglobin or blood pressure can point to hidden bleeding (edoxaban SmPC, EMA).

Management

The edoxaban summary of product characteristics (SmPC) does not recommend long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) with edoxaban (edoxaban SmPC, European Medicines Agency, ). If naproxen is still prescribed, use the lowest effective dose for the shortest time (naproxen SmPC). Give naproxen under close observation to patients who take drugs that affect haemostasis (naproxen SmPC). If long-term NSAID treatment cannot be avoided, monitor carefully for bleeding and promptly evaluate any sign of blood loss (edoxaban prescribing information, US Food and Drug Administration, ). Give naproxen with gastroprotection (misoprostol or a proton pump inhibitor) to older patients and to those with a previous ulcer. Consider the same protection when other drugs raise the risk of gastrointestinal bleeding (naproxen SmPC). Check creatinine clearance before starting edoxaban and later when clinically indicated (edoxaban SmPC, EMA). Naproxen is not recommended in patients with creatinine clearance below 30 mL/min (naproxen SmPC). Edoxaban is contraindicated in a lesion or condition that carries a significant risk of major bleeding, such as an active or recent gastrointestinal ulcer (edoxaban SmPC, EMA). Naproxen is contraindicated in active or recurrent peptic ulcer or bleeding and after previous NSAID-related bleeding (naproxen SmPC). Stop naproxen at once if gastrointestinal bleeding or an ulcer occurs (naproxen SmPC). In severe bleeding, interrupt edoxaban as well (edoxaban SmPC, EMA).

Pair details →Naproxen →

MajorRifampicinAntituberculous antibiotic

Mechanism

Edoxaban is a substrate of P-glycoprotein (P-gp), an efflux transporter. Rifampicin strongly induces drug-metabolising enzymes and transporters, including P-gp (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ; rifampicin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Rifampicin given with edoxaban lowered the mean edoxaban area under the concentration–time curve (AUC) and shortened its half-life. The effect of edoxaban may weaken (edoxaban SmPC, EMA). In the European Heart Rhythm Association table, edoxaban AUC with rifampicin is 35% lower, while its active metabolites rise to compensate (EHRA 2021). Rifampicin itself can cause vitamin K-dependent coagulopathy and severe bleeding (rifampicin SmPC, AEMPS).

Symptoms

The main risk is weaker protection against clots. In atrial fibrillation, this means ischaemic stroke or systemic embolism, and in venous thromboembolism a recurrence of deep vein thrombosis or pulmonary embolism. Signs include leg swelling and pain, sudden shortness of breath and chest pain, sudden weakness or numbness of an arm, a leg or one side of the face, and difficulty speaking. Bleeding is possible as well. Rifampicin can cause vitamin K-dependent coagulopathy and severe bleeding (rifampicin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Edoxaban itself increases the risk of bleeding, including severe and life-threatening bleeding (edoxaban SmPC, European Medicines Agency, ).

Management

Avoid combining edoxaban with rifampicin (edoxaban label, US Food and Drug Administration, ). The European edoxaban summary of product characteristics (SmPC) lists rifampicin among the P-glycoprotein (P-gp) inducers that call for caution with edoxaban (edoxaban SmPC, European Medicines Agency, ). The European Heart Rhythm Association table also requires caution for this pair, especially with polypharmacy or with two or more interactions that lower anticoagulant levels (EHRA 2021). The dosing section of the edoxaban SmPC lists only reasons to reduce the dose to 30 mg. It gives no specific dose for use with inducers (edoxaban SmPC, EMA). If edoxaban is stopped because of rifampicin, keep anticoagulation continuous and switch to another anticoagulant as the edoxaban SmPC describes (EMA). Stopping an oral anticoagulant early without adequate replacement increases the risk of ischaemic events (edoxaban label, FDA). Rifampicin also lowers exposure to other oral anticoagulants, such as warfarin (rifampicin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Rifampicin can cause vitamin K-dependent coagulopathy, so monitor for it in patients at particular risk of bleeding. Consider vitamin K supplementation in vitamin K deficiency and hypoprothrombinaemia (rifampicin SmPC, AEMPS).

Pair details →Rifampicin →

ModerateAmiodaroneClass III antiarrhythmics (Vaughan Williams)

Mechanism

Edoxaban is a substrate of P-glycoprotein (P-gp), an efflux transporter (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). Amiodarone and its metabolite desethylamiodarone inhibit P-gp. According to the amiodarone SmPC, plasma levels of P-gp substrates are expected to rise when they are given with amiodarone (amiodarone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Amiodarone 400 mg once daily with edoxaban 60 mg once daily raised the edoxaban area under the concentration–time curve (AUC) by 40% and peak concentration by 66% (edoxaban SmPC, EMA). This rise was not considered clinically significant. In the ENGAGE AF-TIMI 48 trial in non-valvular atrial fibrillation, edoxaban efficacy and safety were similar with and without amiodarone (edoxaban SmPC, EMA). Because of the long half-life of amiodarone, interactions can occur for several months after it is stopped (amiodarone SmPC, AEMPS).

Symptoms

Edoxaban increases the risk of bleeding and can cause severe, potentially fatal bleeding (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). The most frequently reported adverse reactions with edoxaban are nosebleeds (7.7%), blood in the urine (6.9%) and anaemia (5.3%). Common adverse reactions also include gastrointestinal bleeding, bleeding in the mouth and throat, vaginal bleeding, and bleeding into the skin and soft tissues (edoxaban SmPC, EMA). Bleeding complications can present as weakness, pallor, dizziness, headache, unexplained swelling, shortness of breath or shock of unknown cause (edoxaban SmPC, EMA).

Management

The combination is not contraindicated, and amiodarone does not call for a lower edoxaban dose. The European edoxaban summary of product characteristics (SmPC) recommends 60 mg once daily unless there is another reason for 30 mg once daily. The other reasons are creatinine clearance of 15–50 mL/min, body weight of 60 kg or less, or ciclosporin, dronedarone, erythromycin or ketoconazole (edoxaban SmPC, European Medicines Agency, ). According to the US label, the edoxaban dose for atrial fibrillation is not reduced because of P-glycoprotein (P-gp) inhibitors either (edoxaban label, US Food and Drug Administration, ). In the European Heart Rhythm Association practical guide, the pair is marked yellow (EHRA 2021). Edoxaban exposure rises by 40%. EHRA states that caution is required, especially with polypharmacy or with two or more bleeding risk factors. Examples include age 75 years or older, chronic kidney disease, antiplatelet drugs, non-steroidal anti-inflammatory drugs, systemic steroids, and previous bleeding or a predisposition to it (EHRA 2021). Watch for signs of bleeding and anaemia during treatment. If haemoglobin or blood pressure falls without explanation, look for a bleeding site, and stop edoxaban if severe bleeding occurs (edoxaban SmPC, EMA). Interactions with amiodarone can persist for several months after it is stopped (amiodarone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Check creatinine clearance at the start of treatment in all patients and later when clinically indicated (edoxaban SmPC, EMA).

Pair details →Amiodarone →

ModerateCitalopramSSRI (selective serotonin reuptake inhibitor)

Mechanism

Edoxaban selectively, directly and reversibly inhibits coagulation factor Xa (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). Citalopram is a selective serotonin reuptake inhibitor (SSRI). Drugs that interfere with serotonin reuptake, citalopram included, increase the risk of bleeding, and anticoagulants may add to this risk (US citalopram prescribing information, US Food and Drug Administration, ). For this reason the citalopram SmPC recommends caution in patients who take anticoagulants at the same time (citalopram SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The edoxaban SmPC warns that, as with other anticoagulants, SSRIs may raise the risk of bleeding through their reported effect on platelets (edoxaban SmPC, EMA). No clinical or pharmacokinetic data are available for edoxaban with these antidepressants (European Heart Rhythm Association practical guide, EHRA 2021).

Symptoms

The risk of bleeding rises. Bleeding can occur at any site and may be severe or even fatal (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). The most frequently reported adverse reactions with edoxaban are nosebleeds, blood in the urine and anaemia (EMA). Bleeding complications may present as weakness, pallor, dizziness, headache, unexplained swelling, shortness of breath or shock with no apparent cause (EMA). Changes in skin bleeding time, bruising, and gynaecological, gastrointestinal and other skin or mucosal bleeding have been described with selective serotonin reuptake inhibitors (SSRIs), citalopram included (citalopram SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Such bleeding has ranged from bruising, haematoma, nosebleeds and petechiae to life-threatening haemorrhage (US citalopram prescribing information, US Food and Drug Administration, ).

Management

The combination is not contraindicated, but, as with other anticoagulants, use edoxaban with caution in patients at increased risk of bleeding (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). Use citalopram with caution in patients who take anticoagulants and in patients with a history of bleeding disorders (citalopram SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Warn the patient about the increased risk of bleeding (US citalopram prescribing information, US Food and Drug Administration, ). The European Heart Rhythm Association (EHRA) states that caution is required, especially with polypharmacy or with two or more bleeding risk factors. Examples include antiplatelet drugs, non-steroidal anti-inflammatory drugs, systemic steroids, previous bleeding or a predisposition to it (anaemia, thrombocytopenia), severe frailty and risk of falls (EHRA 2021). Promptly evaluate any signs or symptoms of blood loss (US edoxaban prescribing information, FDA). With edoxaban, standard coagulation tests change little and vary widely, so they are not useful for monitoring its effect (edoxaban SmPC, EMA). Haemoglobin and haematocrit may help detect hidden bleeding. If haemoglobin or blood pressure falls without explanation, look for a bleeding site, and stop edoxaban if severe bleeding occurs (EMA).

Pair details →Citalopram →

ModerateDuloxetineSNRI

Mechanism

Edoxaban selectively, directly and reversibly inhibits coagulation factor Xa (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). Duloxetine is a serotonin and noradrenaline reuptake inhibitor (SNRI). When duloxetine is combined with oral anticoagulants, the risk of bleeding may rise because of a pharmacodynamic interaction (duloxetine SmPC, EMA). Serotonin released by platelets is involved in haemostasis, and drugs that interfere with serotonin reuptake, duloxetine included, may increase the risk of bleeding, and anticoagulants may add to this risk (US duloxetine prescribing information, US Food and Drug Administration, ). The edoxaban SmPC warns that, as with other anticoagulants, SNRIs may raise the risk of bleeding through their reported effect on platelets (edoxaban SmPC, EMA). No clinical or pharmacokinetic data are available for edoxaban with these antidepressants (European Heart Rhythm Association practical guide, EHRA 2021).

Symptoms

The risk of bleeding rises. Bleeding can occur at any site and may be severe or even fatal (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). The most frequently reported adverse reactions with edoxaban are nosebleeds, blood in the urine and anaemia (EMA). Bleeding complications may present as weakness, pallor, dizziness, headache, unexplained swelling, shortness of breath or shock with no apparent cause (EMA). Bruising, purpura and gastrointestinal bleeding have been reported with selective serotonin reuptake inhibitors and serotonin and noradrenaline reuptake inhibitors (SNRIs), duloxetine included (duloxetine SmPC, European Medicines Agency, EMA). Such bleeding has ranged from bruising, haematomas, nosebleeds and petechiae to life-threatening haemorrhage (US duloxetine prescribing information, US Food and Drug Administration, ).

Management

The combination is not contraindicated, but, as with other anticoagulants, use edoxaban with caution in patients at increased risk of bleeding (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). Use caution when duloxetine is combined with oral anticoagulants and in patients with a known bleeding tendency (duloxetine SmPC, EMA). Warn the patient about the increased risk of bleeding when duloxetine is combined with drugs that affect coagulation (US duloxetine prescribing information, US Food and Drug Administration, ). The European Heart Rhythm Association (EHRA) states that caution is required, especially with polypharmacy or with two or more bleeding risk factors. Examples include antiplatelet drugs, non-steroidal anti-inflammatory drugs, systemic steroids, previous bleeding or a predisposition to it (anaemia, thrombocytopenia), severe frailty and risk of falls (EHRA 2021). Promptly evaluate any signs or symptoms of blood loss (US edoxaban prescribing information, FDA). With edoxaban, standard coagulation tests change little and vary widely, so they are not useful for monitoring its effect (edoxaban SmPC, EMA). Haemoglobin and haematocrit may help detect hidden bleeding. If haemoglobin or blood pressure falls without explanation, look for a bleeding site, and stop edoxaban if severe bleeding occurs (EMA).

Pair details →Duloxetine →

ModerateEscitalopramSelective serotonin reuptake inhibitors (SSRIs)

Mechanism

Edoxaban selectively, directly and reversibly inhibits coagulation factor Xa (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). Drugs that interfere with serotonin reuptake, escitalopram included, increase the risk of bleeding (US escitalopram prescribing information, US Food and Drug Administration, ). Combined with oral anticoagulants, escitalopram may alter their effects (escitalopram SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The edoxaban SmPC warns that, as with other anticoagulants, selective serotonin reuptake inhibitors (SSRIs) may raise the risk of bleeding through their reported effect on platelets (EMA). No clinical or pharmacokinetic data are available for edoxaban with these antidepressants (European Heart Rhythm Association practical guide, EHRA 2021).

Symptoms

The risk of bleeding rises. Bleeding can occur at any site and may be severe or even fatal (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). The most frequently reported adverse reactions with edoxaban are nosebleeds, blood in the urine and anaemia (EMA). Bleeding complications may present as weakness, pallor, dizziness, headache, unexplained swelling, shortness of breath or shock with no apparent cause (EMA). Bleeding into the skin, such as bruising and purpura, has been described with selective serotonin reuptake inhibitors (SSRIs). Nosebleeds and gastrointestinal bleeding, including rectal bleeding, are uncommon adverse reactions of escitalopram (escitalopram SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).

Management

The combination is not contraindicated, but, as with other anticoagulants, use edoxaban with caution in patients at increased risk of bleeding (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). Use escitalopram with caution, especially together with oral anticoagulants and in patients with a tendency to bleed. When escitalopram is started or stopped in a patient taking an oral anticoagulant, monitor coagulation closely (escitalopram SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). With edoxaban, standard coagulation tests change little and vary widely, so they are not useful for monitoring its effect (edoxaban SmPC, EMA). Edoxaban does not need routine monitoring (EMA). In specific situations such as overdose or emergency surgery, a calibrated quantitative anti-factor Xa assay can help (EMA). The European Heart Rhythm Association (EHRA) states that caution is required, especially with polypharmacy or with two or more bleeding risk factors. Examples include antiplatelet drugs, non-steroidal anti-inflammatory drugs, systemic steroids, previous bleeding or a predisposition to it (anaemia, thrombocytopenia), severe frailty and risk of falls (EHRA 2021). Warn the patient about the increased risk of bleeding (US escitalopram prescribing information, US Food and Drug Administration, ). Promptly evaluate any signs or symptoms of blood loss (US edoxaban prescribing information, FDA). Haemoglobin and haematocrit may help detect hidden bleeding. If haemoglobin or blood pressure falls without explanation, look for a bleeding site, and stop edoxaban if severe bleeding occurs (edoxaban SmPC, EMA).

Pair details →Escitalopram →

ModerateFluoxetineSelective serotonin reuptake inhibitors

Mechanism

Edoxaban selectively, directly and reversibly inhibits coagulation factor Xa (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). Fluoxetine carries a risk of increased bleeding when combined with drugs that affect haemostasis, including oral anticoagulants of any mechanism (fluoxetine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The edoxaban SmPC warns that, as with other anticoagulants, selective serotonin reuptake inhibitors (SSRIs) may raise the risk of bleeding through their reported effect on platelets (EMA). Fluoxetine and its active metabolite norfluoxetine are eliminated slowly and remain in the body for 5–6 weeks after the drug is stopped (fluoxetine SmPC, AEMPS). No clinical or pharmacokinetic data are available for edoxaban with these antidepressants (European Heart Rhythm Association practical guide, EHRA 2021).

Symptoms

The risk of bleeding rises. Bleeding can occur at any site and may be severe or even fatal (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). The most frequently reported adverse reactions with edoxaban are nosebleeds, blood in the urine and anaemia (EMA). Bleeding complications may present as weakness, pallor, dizziness, headache, unexplained swelling, shortness of breath or shock with no apparent cause (EMA). Bleeding into the skin, such as bruising and purpura, occurs with selective serotonin reuptake inhibitors (SSRIs). With fluoxetine, bruising is uncommon, and gynaecological, gastrointestinal and other skin or mucosal bleeding has been reported rarely (fluoxetine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).

Management

The combination is not contraindicated, but, as with other anticoagulants, use edoxaban with caution in patients at increased risk of bleeding (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). Use fluoxetine with caution, especially together with oral anticoagulants and in patients with a history of bleeding disorders (fluoxetine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). For patients taking an oral anticoagulant, the fluoxetine SmPC asks for more frequent clinical monitoring of the INR, the international normalised ratio (AEMPS). With edoxaban, however, the INR and other standard coagulation tests change little and vary widely, so they are not useful for monitoring its effect (edoxaban SmPC, EMA). When assessing interactions, take into account the long half-lives of fluoxetine and norfluoxetine. Fluoxetine remains in the body for 5–6 weeks after it is stopped (fluoxetine SmPC, AEMPS). The European Heart Rhythm Association (EHRA) states that caution is required, especially with polypharmacy or with two or more bleeding risk factors. Examples include antiplatelet drugs, non-steroidal anti-inflammatory drugs, systemic steroids, previous bleeding or a predisposition to it (anaemia, thrombocytopenia), severe frailty and risk of falls (EHRA 2021). Promptly evaluate any signs or symptoms of blood loss (US edoxaban prescribing information, US Food and Drug Administration, ). Haemoglobin and haematocrit may help detect hidden bleeding. If haemoglobin or blood pressure falls without explanation, look for a bleeding site, and stop edoxaban if severe bleeding occurs (edoxaban SmPC, EMA).

Pair details →Fluoxetine →

ModerateFluvoxamineSSRI

Mechanism

Edoxaban selectively, directly and reversibly inhibits coagulation factor Xa (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI). Serotonin released by platelets is involved in haemostasis, and SSRIs, fluvoxamine included, may increase the risk of bleeding, and anticoagulants may add to this risk (US fluvoxamine prescribing information, US Food and Drug Administration, ). The fluvoxamine SmPC states that in patients taking oral anticoagulants the risk of bleeding may increase (fluvoxamine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The edoxaban SmPC warns that, as with other anticoagulants, SSRIs may raise the risk of bleeding through their reported effect on platelets (edoxaban SmPC, EMA). No clinical or pharmacokinetic data are available for edoxaban with these antidepressants (European Heart Rhythm Association practical guide, EHRA 2021).

Symptoms

The risk of bleeding rises. Bleeding can occur at any site and may be severe or even fatal (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). The most frequently reported adverse reactions with edoxaban are nosebleeds, blood in the urine and anaemia (EMA). Bleeding complications may present as weakness, pallor, dizziness, headache, unexplained swelling, shortness of breath or shock with no apparent cause (EMA). Gastrointestinal, gynaecological and other skin or mucosal bleeding has been described with selective serotonin reuptake inhibitors (SSRIs), fluvoxamine included (fluvoxamine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Such bleeding has ranged from bruising, haematomas, nosebleeds and petechiae to life-threatening haemorrhage (US fluvoxamine prescribing information, US Food and Drug Administration, ).

Management

The combination is not contraindicated, but, as with other anticoagulants, use edoxaban with caution in patients at increased risk of bleeding (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). Monitor patients taking fluvoxamine with oral anticoagulants closely, because the risk of bleeding may increase (fluvoxamine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Take particular care in older patients, in patients with previous bleeding and in conditions that predispose to bleeding, such as thrombocytopenia or coagulation disorders (AEMPS). Warn the patient about the increased risk of bleeding when fluvoxamine is combined with drugs that affect coagulation (US fluvoxamine prescribing information, US Food and Drug Administration, ). The European Heart Rhythm Association (EHRA) states that caution is required, especially with polypharmacy or with two or more bleeding risk factors. Examples include antiplatelet drugs, non-steroidal anti-inflammatory drugs, systemic steroids, previous bleeding or a predisposition to it (anaemia, thrombocytopenia), severe frailty and risk of falls (EHRA 2021). Promptly evaluate any signs or symptoms of blood loss (US edoxaban prescribing information, FDA). With edoxaban, standard coagulation tests change little and vary widely, so they are not useful for monitoring its effect (edoxaban SmPC, EMA). Haemoglobin and haematocrit may help detect hidden bleeding. If haemoglobin or blood pressure falls without explanation, look for a bleeding site, and stop edoxaban if severe bleeding occurs (EMA).

Pair details →Fluvoxamine →

ModerateParoxetineSelective serotonin reuptake inhibitor (SSRI)

Mechanism

Edoxaban selectively, directly and reversibly inhibits coagulation factor Xa (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). Paroxetine is a selective serotonin reuptake inhibitor (SSRI). A pharmacodynamic interaction may occur between paroxetine and oral anticoagulants: together they may increase anticoagulant activity and the risk of bleeding (paroxetine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Drugs that interfere with serotonin reuptake, paroxetine included, increase the risk of bleeding, and anticoagulants may add to this risk (US paroxetine prescribing information, US Food and Drug Administration, ). The edoxaban SmPC warns that, as with other anticoagulants, SSRIs may raise the risk of bleeding through their reported effect on platelets (edoxaban SmPC, EMA). No clinical or pharmacokinetic data are available for edoxaban with these antidepressants (European Heart Rhythm Association practical guide, EHRA 2021).

Symptoms

The risk of bleeding rises. Bleeding can occur at any site and may be severe or even fatal (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). The most frequently reported adverse reactions with edoxaban are nosebleeds, blood in the urine and anaemia (EMA). Bleeding complications may present as weakness, pallor, dizziness, headache, unexplained swelling, shortness of breath or shock with no apparent cause (EMA). Bleeding into the skin (bruising and purpura) and gastrointestinal and gynaecological bleeding have been reported with selective serotonin reuptake inhibitors (SSRIs), paroxetine included. Older patients may have a higher risk of non-menstrual bleeding (paroxetine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Such bleeding has ranged from bruising, haematomas, nosebleeds and petechiae to life-threatening haemorrhage (US paroxetine prescribing information, US Food and Drug Administration, ).

Management

The combination is not contraindicated, but, as with other anticoagulants, use edoxaban with caution in patients at increased risk of bleeding (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). Use paroxetine with caution in patients taking oral anticoagulants and in patients with previous bleeding or conditions that predispose to bleeding (paroxetine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Warn the patient about the increased risk of bleeding (US paroxetine prescribing information, US Food and Drug Administration, ). The European Heart Rhythm Association (EHRA) states that caution is required, especially with polypharmacy or with two or more bleeding risk factors. Examples include antiplatelet drugs, non-steroidal anti-inflammatory drugs, systemic steroids, previous bleeding or a predisposition to it (anaemia, thrombocytopenia), severe frailty and risk of falls (EHRA 2021). Promptly evaluate any signs or symptoms of blood loss (US edoxaban prescribing information, FDA). With edoxaban, standard coagulation tests change little and vary widely, so they are not useful for monitoring its effect (edoxaban SmPC, EMA). Haemoglobin and haematocrit may help detect hidden bleeding. If haemoglobin or blood pressure falls without explanation, look for a bleeding site, and stop edoxaban if severe bleeding occurs (EMA).

Pair details →Paroxetine →

ModeratePhenytoinAntiepileptic, hydantoin derivative (sodium channel blocker)

Mechanism

Edoxaban is a substrate of P-glycoprotein (P-gp), an efflux transporter. Phenytoin is one of the P-gp inducers that may lower edoxaban plasma levels (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). Edoxaban also appears in the phenytoin documents. The Spanish SmPC lists it among the drugs whose levels or effects phenytoin may alter (phenytoin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US label lists it among the drugs whose levels phenytoin decreases (phenytoin label, US Food and Drug Administration, ). Neither the labels nor the European Heart Rhythm Association table says how much edoxaban levels fall (EHRA 2021).

Symptoms

The main risk is thrombosis because edoxaban works less well. In atrial fibrillation, this means ischaemic stroke or systemic embolism, and in venous thromboembolism a recurrence of deep vein thrombosis or pulmonary embolism. Signs include leg swelling and pain, sudden shortness of breath and chest pain, sudden weakness or numbness of an arm, a leg or one side of the face, and difficulty speaking. The European Heart Rhythm Association guide also reports the opposite signal for direct oral anticoagulants as a group. In one case series, the risk of bleeding with phenytoin was higher. In a retrospective cohort from Taiwan, bleeding was more frequent when phenytoin was prescribed at the same time. The authors note that this result may not apply to other patient groups (EHRA 2021).

Management

Use caution when edoxaban is combined with P-glycoprotein (P-gp) inducers, phenytoin included (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). The European Heart Rhythm Association table also requires caution for this pair, especially with polypharmacy or with two or more interactions that lower anticoagulant levels (EHRA 2021). When phenytoin is started or stopped, the dose of edoxaban and other drugs on the US label's list may need adjustment (phenytoin label, US Food and Drug Administration, ). The dosing section of the edoxaban SmPC lists only reasons to reduce the dose to 30 mg. It gives no specific dose for use with inducers (edoxaban SmPC, EMA). Phenytoin may also alter the levels or effects of other oral anticoagulants: warfarin, apixaban, dabigatran and rivaroxaban (phenytoin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).

Pair details →Phenytoin →

ModerateSertralineSelective serotonin reuptake inhibitors (SSRIs)

Mechanism

Edoxaban selectively, directly and reversibly inhibits coagulation factor Xa (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). At clinical doses, sertraline blocks serotonin uptake by human platelets (sertraline SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Drugs that interfere with serotonin reuptake, sertraline included, increase the risk of bleeding (US sertraline prescribing information, US Food and Drug Administration, ). The edoxaban SmPC warns that, as with other anticoagulants, selective serotonin reuptake inhibitors (SSRIs) may raise the risk of bleeding through their reported effect on platelets (EMA). No clinical or pharmacokinetic data are available for edoxaban with these antidepressants (European Heart Rhythm Association practical guide, EHRA 2021).

Symptoms

The risk of bleeding rises. Bleeding can occur at any site and may be severe or even fatal (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). The most frequently reported adverse reactions with edoxaban are nosebleeds, blood in the urine and anaemia (EMA). Bleeding complications may present as weakness, pallor, dizziness, headache, unexplained swelling, shortness of breath or shock with no apparent cause (EMA). Patients taking selective serotonin reuptake inhibitors (SSRIs), sertraline included, have had bleeding into the skin (bruising and purpura) and gastrointestinal and gynaecological bleeding, including fatal bleeding (sertraline SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).

Management

The combination is not contraindicated, but, as with other anticoagulants, use edoxaban with caution in patients at increased risk of bleeding (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). Use sertraline with caution, especially together with anticoagulants and in patients with a history of bleeding disorders (sertraline SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The European Heart Rhythm Association (EHRA) states that caution is required, especially with polypharmacy or with two or more bleeding risk factors. Examples include antiplatelet drugs, non-steroidal anti-inflammatory drugs, systemic steroids, previous bleeding or a predisposition to it (anaemia, thrombocytopenia), severe frailty and risk of falls (EHRA 2021). Warn the patient about the increased risk of bleeding (US sertraline prescribing information, US Food and Drug Administration, ). Promptly evaluate any signs or symptoms of blood loss (US edoxaban prescribing information, FDA). With edoxaban, standard coagulation tests change little and vary widely, so they are not useful for monitoring its effect (edoxaban SmPC, EMA). Haemoglobin and haematocrit may help detect hidden bleeding. If haemoglobin or blood pressure falls without explanation, look for a bleeding site, and stop edoxaban if severe bleeding occurs (EMA).

Pair details →Sertraline →

ModerateTicagrelorReversible P2Y12 receptor inhibitor

Mechanism

Edoxaban directly and reversibly inhibits coagulation factor Xa (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). Ticagrelor reversibly blocks the platelet P2Y12 receptor and so prevents platelet activation and aggregation (ticagrelor SmPC, EMA). The edoxaban SmPC lists P2Y12 inhibitors among drugs that affect haemostasis and may increase the risk of bleeding (EMA). Ticagrelor weakly inhibits P-glycoprotein (P-gp) and may increase exposure to P-gp substrates. Edoxaban is a P-gp substrate. The effect of ticagrelor on edoxaban levels has not been studied (ticagrelor and edoxaban SmPCs, EMA).

Symptoms

The risk of bleeding rises. Bleeding can occur at any site and may be severe or even fatal (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). The most frequently reported adverse reactions with edoxaban are nosebleeds, blood in the urine and anaemia. Common adverse reactions also include gastrointestinal bleeding, bleeding in the mouth and throat, bleeding into the skin and soft tissues, and vaginal bleeding (EMA). Bleeding complications may present as weakness, pallor, dizziness, headache, unexplained swelling, shortness of breath or shock with no apparent cause (EMA).

Management

There is no contraindication for this pair. If the combination is clinically indicated, use ticagrelor with caution. This applies to patients who, within 24 hours of a ticagrelor dose, take drugs that may increase the risk of bleeding, oral anticoagulants included. In patients at known high risk of bleeding, weigh the benefit of ticagrelor against that risk (ticagrelor summary of product characteristics, SmPC, European Medicines Agency, ). Ticagrelor is taken with a low maintenance dose of acetylsalicylic acid, 75–150 mg a day, unless acetylsalicylic acid is contraindicated (EMA). Experience with edoxaban and dual antiplatelet therapy is very limited (edoxaban SmPC, EMA). Ticagrelor is not among the P-glycoprotein (P-gp) inhibitors that call for reducing the edoxaban dose to 30 mg once daily (ciclosporin, dronedarone, erythromycin, ketoconazole). Edoxaban has not been studied with other P-gp inhibitors (EMA). If haemoglobin or blood pressure falls without explanation, look for a bleeding site, and stop edoxaban if severe bleeding occurs (EMA). Before elective surgery, if an antiplatelet effect is not needed, stop ticagrelor 5 days in advance (ticagrelor SmPC, EMA). If anticoagulation has to be interrupted, stop edoxaban as early as possible, preferably at least 24 hours before the procedure (edoxaban SmPC, EMA). According to the US edoxaban label, promptly evaluate any sign or symptom of blood loss in patients who also take other platelet aggregation inhibitors (edoxaban prescribing information, US Food and Drug Administration, ).

Pair details →Ticagrelor →

ModerateTramadolOther opioids

Mechanism

Edoxaban is a direct inhibitor of clotting factor Xa and by itself increases the bleeding risk (edoxaban summary of product characteristics, SmPC, European Medicines Agency, , sections 4.4 and 5.1). Drugs that affect haemostasis may increase this risk, and the edoxaban documents list serotonin and noradrenaline reuptake inhibitors (SNRIs) among them. As with other anticoagulants, the bleeding risk with SNRIs may be higher because of their reported effect on platelets (EMA, sections 4.4 and 4.5; edoxaban label, US Food and Drug Administration, , section 7.1). Tramadol is an opioid that, according to its US label, also weakly inhibits the reuptake of serotonin and noradrenaline (tramadol FDA label, sections 5.7 and 12.1). The documents do not address the combination of edoxaban and tramadol directly. The tramadol documents discuss bleeding only in connection with warfarin and other coumarins (tramadol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). The documents also say nothing about either drug changing the levels of the other. Edoxaban is a substrate of the transporter P-glycoprotein (P-gp) and circulates mainly unchanged. CYP3A4 metabolises only a small part of it, and about half of its clearance is renal. The edoxaban documents do not list tramadol among P-gp inhibitors or inducers. In vitro, edoxaban did not inhibit CYP2D6 or CYP3A4, which metabolise tramadol (EMA, sections 4.5 and 5.2; FDA, section 12.3; AEMPS, section 5.2).

Symptoms

The documents describe no symptoms linked to this combination. The main risk of edoxaban is bleeding. The most frequent adverse reactions are nosebleeds (7.7%), blood in the urine (6.9%) and anaemia (5.3%). Bleeding can occur at any site and can be severe or even fatal (edoxaban summary of product characteristics, SmPC, European Medicines Agency, , section 4.8; edoxaban label, US Food and Drug Administration, , section 5.3). The most frequent adverse effects of tramadol are nausea and dizziness, seen in more than 10% of patients. Headache, drowsiness, constipation, dry mouth, vomiting and sweating are common (tramadol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.8).

Management

The documents do not address this combination directly. The edoxaban documents list serotonin and noradrenaline reuptake inhibitors (SNRIs) among the drugs that affect haemostasis and may increase the bleeding risk. Edoxaban is used with caution in people at increased risk of bleeding (edoxaban summary of product characteristics, SmPC, European Medicines Agency, , sections 4.4 and 4.5). Tramadol, according to its US label, weakly inhibits the reuptake of serotonin and noradrenaline (tramadol label, US Food and Drug Administration, , section 5.7). The combination is therefore managed with the same caution. Any signs or symptoms of blood loss are evaluated promptly (edoxaban FDA label, section 5.3), and edoxaban is stopped if severe bleeding occurs (EMA, section 4.4). An unexplained fall in haemoglobin or blood pressure calls for a search for a bleeding site (EMA, section 4.4). The documents give no reason to change the edoxaban dose. Among concomitant drugs, only certain inhibitors of the transporter P-glycoprotein (P-gp), named explicitly in the SmPC, require a reduction to 30 mg. Tramadol is not among them (EMA, section 4.5).

Pair details →Tramadol →

ModerateVenlafaxineSNRI (serotonin-norepinephrine reuptake inhibitor)

Mechanism

Edoxaban selectively, directly and reversibly inhibits coagulation factor Xa (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). Drugs that inhibit serotonin uptake may reduce platelet function, and the risk of bleeding may increase in patients taking venlafaxine (venlafaxine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). With an anticoagulant, venlafaxine may increase the risk of bleeding, possibly through its effect on serotonin release by platelets (US venlafaxine prescribing information, US Food and Drug Administration, ). Venlafaxine belongs to the serotonin and noradrenaline reuptake inhibitors (SNRIs). The edoxaban SmPC warns that, as with other anticoagulants, SNRIs may raise the risk of bleeding through their reported effect on platelets (EMA). No clinical or pharmacokinetic data are available for edoxaban with these antidepressants (European Heart Rhythm Association practical guide, EHRA 2021).

Symptoms

The risk of bleeding rises. Bleeding can occur at any site and may be severe or even fatal (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). The most frequently reported adverse reactions with edoxaban are nosebleeds, blood in the urine and anaemia (EMA). Bleeding complications may present as weakness, pallor, dizziness, headache, unexplained swelling, shortness of breath or shock with no apparent cause (EMA). Bleeding linked to selective serotonin reuptake inhibitors and serotonin and noradrenaline reuptake inhibitors ranges from bruising, haematomas, nosebleeds and petechiae to life-threatening gastrointestinal bleeding (venlafaxine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).

Management

The combination is not contraindicated, but, as with other anticoagulants, use edoxaban with caution in patients at increased risk of bleeding (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). As with other serotonin reuptake inhibitors, use venlafaxine with caution in patients predisposed to bleeding, including those taking anticoagulants (venlafaxine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). When venlafaxine is started or stopped in a patient taking an anticoagulant, monitor closely for bleeding. Warn the patient about the increased risk of bleeding (US venlafaxine prescribing information, US Food and Drug Administration, ). The European Heart Rhythm Association (EHRA) states that caution is required, especially with polypharmacy or with two or more bleeding risk factors. Examples include antiplatelet drugs, non-steroidal anti-inflammatory drugs, systemic steroids, previous bleeding or a predisposition to it (anaemia, thrombocytopenia), severe frailty and risk of falls (EHRA 2021). Promptly evaluate any signs or symptoms of blood loss (US edoxaban prescribing information, FDA). With edoxaban, standard coagulation tests change little and vary widely, so they are not useful for monitoring its effect (edoxaban SmPC, EMA). Haemoglobin and haematocrit may help detect hidden bleeding. If haemoglobin or blood pressure falls without explanation, look for a bleeding site, and stop edoxaban if severe bleeding occurs (EMA).

Pair details →Venlafaxine →

ModerateVerapamilNon-dihydropyridine calcium channel blocker

Mechanism

Edoxaban is a substrate of P-glycoprotein (P-gp), an efflux transporter (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). Verapamil inhibits P-gp and the enzyme CYP3A4 (verapamil SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Verapamil 240 mg once daily for 11 days raised the edoxaban area under the concentration–time curve (AUC) and peak concentration by about 53% (edoxaban SmPC, EMA). According to the verapamil SmPC, direct oral anticoagulants are absorbed to a greater extent because they are P-gp substrates. Some data suggest that the risk of bleeding may rise, especially in patients with risk factors (verapamil SmPC, AEMPS). Edoxaban in turn lowered verapamil peak concentration by 14% and AUC by 16% (edoxaban SmPC, EMA).

Symptoms

Edoxaban increases the risk of bleeding and can cause severe, potentially fatal bleeding (edoxaban summary of product characteristics, SmPC, European Medicines Agency, ). The most frequently reported adverse reactions with edoxaban are nosebleeds (7.7%), blood in the urine (6.9%) and anaemia (5.3%). Common adverse reactions also include gastrointestinal bleeding, bleeding in the mouth and throat, vaginal bleeding, and bleeding into the skin and soft tissues (edoxaban SmPC, EMA). Bleeding complications can present as weakness, pallor, dizziness, headache, unexplained swelling, shortness of breath or shock of unknown cause (edoxaban SmPC, EMA).

Management

The combination is not contraindicated. Under the European edoxaban summary of product characteristics (SmPC), verapamil does not call for a lower edoxaban dose (edoxaban SmPC, European Medicines Agency, ). The verapamil SmPC says to reduce the dose of a direct oral anticoagulant, if needed, as that anticoagulant's own SmPC recommends (verapamil SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). In atrial fibrillation and in the treatment and prevention of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE), the edoxaban dose is 60 mg once daily. The 30 mg once-daily dose is only for other reasons: creatinine clearance of 15–50 mL/min, body weight of 60 kg or less, or ciclosporin, dronedarone, erythromycin or ketoconazole (edoxaban SmPC, EMA). The US edoxaban label follows a different scheme. In DVT and PE treatment, patients taking certain P-glycoprotein (P-gp) inhibitors get 30 mg once daily, and in the trial these inhibitors included verapamil. In atrial fibrillation, the dose is not changed for these inhibitors (edoxaban label, US Food and Drug Administration, ). In the European Heart Rhythm Association practical guide, the pair is marked yellow (EHRA 2021). Edoxaban exposure rises by 53%, and the label requires no dose reduction. EHRA states that caution is required, especially with polypharmacy or with two or more bleeding risk factors. Examples include age 75 years or older, chronic kidney disease, antiplatelet drugs, non-steroidal anti-inflammatory drugs, systemic steroids, and previous bleeding or a predisposition to it (EHRA 2021). Watch for signs of bleeding and anaemia during treatment. If haemoglobin or blood pressure falls without explanation, look for a bleeding site, and stop edoxaban if severe bleeding occurs (edoxaban SmPC, EMA). Check creatinine clearance at the start of treatment in all patients and later when clinically indicated (edoxaban SmPC, EMA).

Pair details →Verapamil →

Label mentions40 mentions

Verbatim lines from the interaction sections, in the language of the label

From this drug’s label

  • CriticalApixaban
    «Tratamiento concomitante con cualquier otro anticoagulante, p. ej., HNF, heparinas de bajo peso molecular (enoxaparina, dalteparina, etc.), derivados de la heparina (fondaparinux, etc.)…»

    AEMPS, section 4.3 · Open on CIMA

  • CriticalDabigatran
    «Tratamiento concomitante con cualquier otro anticoagulante, p. ej., HNF, heparinas de bajo peso molecular (enoxaparina, dalteparina, etc.), derivados de la heparina (fondaparinux, etc.)…»

    AEMPS, section 4.3 · Open on CIMA

  • CriticalRivaroxaban
    «Tratamiento concomitante con cualquier otro anticoagulante, p. ej., HNF, heparinas de bajo peso molecular (enoxaparina, dalteparina, etc.), derivados de la heparina (fondaparinux, etc.)…»

    AEMPS, section 4.3 · Open on CIMA

  • CriticalWarfarin
    «Tratamiento concomitante con cualquier otro anticoagulante, p. ej., HNF, heparinas de bajo peso molecular (enoxaparina, dalteparina, etc.), derivados de la heparina (fondaparinux, etc.)…»

    AEMPS, section 4.3 · Open on CIMA

  • MajorAINEclass named in the label
    «AINE: La administración conjunta de naproxeno y edoxabán aumentó el tiempo de sangrado respecto a cada uno de estos medicamentos solos. Naproxeno no tuvo ningún efecto en la C máx o en el AUC de…»

    AEMPS, section 4.5 · Open on CIMA

  • «Inhibidores de la P-gp: Edoxabán es un sustrato del transportador de eflujo P-gp. En los estudios farmacocinéticos, la administración de edoxabán junto con los inhibidores de la P-gp ciclosporina…»

    AEMPS, section 4.5 · Open on CIMA

  • «Inhibidores de la P-gp: Edoxabán es un sustrato del transportador de eflujo P-gp. En los estudios farmacocinéticos, la administración de edoxabán junto con los inhibidores de la P-gp ciclosporina…»

    AEMPS, section 4.5 · Open on CIMA

  • «Inhibidores de la P-gp: Edoxabán es un sustrato del transportador de eflujo P-gp. En los estudios farmacocinéticos, la administración de edoxabán junto con los inhibidores de la P-gp ciclosporina…»

    AEMPS, section 4.5 · Open on CIMA

  • «Inhibidores de la P-gp: Edoxabán es un sustrato del transportador de eflujo P-gp. En los estudios farmacocinéticos, la administración de edoxabán junto con los inhibidores de la P-gp ciclosporina…»

    AEMPS, section 4.5 · Open on CIMA

  • «AINE: La administración conjunta de naproxeno y edoxabán aumentó el tiempo de sangrado respecto a cada uno de estos medicamentos solos. Naproxeno no tuvo ningún efecto en la C máx o en el AUC de…»

    AEMPS, section 4.5 · Open on CIMA

  • «DRUG INTERACTIONS: Rifampin: Avoid concomitant use ( 7.2 )»

    FDA, section 7 · Open on DailyMed

  • «Pacientes de edad avanzada: La administración conjunta de edoxabán y ácido acetilsalicílico (AAS) en pacientes de edad avanzada se debe realizar con precaución debido al riesgo potencialmente mayor…»

    AEMPS, section 4.4 · Open on CIMA

  • «Anticoagulants, Antiplatelets, Thrombolytics, and SSRIs/SNRIs: In clinical studies with SAVAYSA concomitant use of aspirin (low dose ≤ 100 mg/day) or thienopyridines, and NSAIDs was permitted and…»

    FDA, section 7 · Open on DailyMed

  • Moderateantiplateletsclass named in the label
    «DRUG INTERACTIONS: Anticoagulants, Antiplatelets, Thrombolytics, and Selective Serotonin Reuptake Inhibitors (SSRIs)/Serotonin Norepinephrine Reuptake Inhibitors (SNRIs): Avoid concomitant use due to…»

    FDA, section 7 · Open on DailyMed

  • «Inductores de la P-gp: La administración conjunta de edoxabán y el inductor de la P-gp rifampicina produjo una disminución del AUC media de edoxabán y una disminución de la vida media, con posibles…»

    AEMPS, section 4.5 · Open on CIMA

  • ModerateClopidogrel
    «Inhibidores plaquetarios: En el es tudio ENGAGE AF-TIMI 48 se permitió el uso concomitante de tienopiridinas (p. ej., clopidogrel) en monoterapia y produjo un aumento del sangrado clínicamente…»

    AEMPS, section 4.5 · Open on CIMA

  • «Inductores de la P-gp: La administración conjunta de edoxabán y el inductor de la P-gp rifampicina produjo una disminución del AUC media de edoxabán y una disminución de la vida media, con posibles…»

    AEMPS, section 4.5 · Open on CIMA

  • ModerateISRSclass named in the label
    «ISRS/IRSN: Al igual que sucede con otros anticoagulantes, existe la posibilidad de que los pacientes tengan un mayor riesgo de sangrado en caso de uso concomitante con ISRS o ISRN debido a su efecto…»

    AEMPS, section 4.5 · Open on CIMA

  • ModerateNSAIDsclass named in the label
    «Anticoagulants, Antiplatelets, Thrombolytics, and SSRIs/SNRIs: In clinical studies with SAVAYSA concomitant use of aspirin (low dose ≤ 100 mg/day) or thienopyridines, and NSAIDs was permitted and…»

    FDA, section 7 · Open on DailyMed

  • «Inductores de la P-gp: La administración conjunta de edoxabán y el inductor de la P-gp rifampicina produjo una disminución del AUC media de edoxabán y una disminución de la vida media, con posibles…»

    AEMPS, section 4.5 · Open on CIMA

  • ModeratePhenytoin
    «Inductores de la P-gp: La administración conjunta de edoxabán y el inductor de la P-gp rifampicina produjo una disminución del AUC media de edoxabán y una disminución de la vida media, con posibles…»

    AEMPS, section 4.5 · Open on CIMA

  • ModerateRifampicin
    «Inductores de la P-gp: La administración conjunta de edoxabán y el inductor de la P-gp rifampicina produjo una disminución del AUC media de edoxabán y una disminución de la vida media, con posibles…»

    AEMPS, section 4.5 · Open on CIMA

  • ModerateSSRIs/SNRIsclass named in the label
    «DRUG INTERACTIONS: Anticoagulants, Antiplatelets, Thrombolytics, and Selective Serotonin Reuptake Inhibitors (SSRIs)/Serotonin Norepinephrine Reuptake Inhibitors (SNRIs): Avoid concomitant use due to…»

    FDA, section 7 · Open on DailyMed

  • «Inhibidores de la P-gp: Edoxabán es un sustrato del transportador de eflujo P-gp. En los estudios farmacocinéticos, la administración de edoxabán junto con los inhibidores de la P-gp ciclosporina…»

    AEMPS, section 4.5 · Open on CIMA

  • «Inhibidores de la P-gp: Claritromicina: la administración de claritromicina (500 mg dos veces al día) durante 10 días junto con una dosis única de 60 mg de edoxabán el día 9 aumentó el AUC y la C máx…»

    AEMPS, section 4.5 · Open on CIMA

  • MinorDigoxin
    «Digoxina: La administración de 60 mg de edoxabán una vez al día los días 1 a 14 con la administración conjunta de múltiples dosis diarias de 0,25 mg de digoxina dos veces al día (días 8 y 9) y de…»

    AEMPS, section 4.5 · Open on CIMA

  • Minorinhibidores de la proteasa del VIHclass named in the label
    «Inhibidores de la P-gp: No se ha estudiado el uso de edoxabán con otros inhibidores de la P-gp, incluidos los inhibidores de la proteasa del virus de la inmunodeficiencia humana (VIH).»

    AEMPS, section 4.5 · Open on CIMA

  • «Inhibidores de la P-gp: Edoxabán es un sustrato del transportador de eflujo P-gp. En los estudios farmacocinéticos, la administración de edoxabán junto con los inhibidores de la P-gp ciclosporina…»

    AEMPS, section 4.5 · Open on CIMA

  • «Inhibidores de la P-gp: Edoxabán es un sustrato del transportador de eflujo P-gp. En los estudios farmacocinéticos, la administración de edoxabán junto con los inhibidores de la P-gp ciclosporina…»

    AEMPS, section 4.5 · Open on CIMA

From other drugs’ labels

  • «ANTICOAGULANTES / INHIBIDOR DE LA AGREGACIÓN PLAQUETARIA: Darunavir/ritonavir: Se debe considerar la monitorización clínica y/o la reducción de la dosis del ACOD cuando se administra junto con…»

    AEMPS, section 4.5 · Open on CIMA

  • «Interacción con medicamentos que son metabolizados por CYP 3A4 y Gp-P: En estudios in vivo , la exposición a edoxaban (un sustrato de CYP3A4 y Gp-P) aumentó cuando se administró con dronedarona. La…»

    AEMPS, section 4.5 · Open on CIMA

  • «Inhibidores directos del factor Xa (p. ej., apixaban, rivaroxaban, edoxaban).»

    AEMPS, section 4.5 · Open on CIMA

  • ModerateAtazanavir
    «Edoxaban: Posible aumento de las concentraciones de edoxaban, lo que puede llevar a un aumento del riesgo de sangrado. El mecanismo de interacción es la inhibición de la gp ‑ P por REYATAZ/ritonavir…»

    AEMPS, section 4.5 · Open on CIMA

  • ModerateAtazanavir
    «Established and Other Potentially Significant Drug Interactions: Direct-Acting Oral Anticoagulants: betrixaban, dabigatran, edoxaban ↑ betrixaban ↑ dabigatran ↑ edoxaban Concomitant use of atazanavir…»

    FDA, section 7 · Open on DailyMed

  • «Combinaciones que requieren una consideración específica: El uso concomitante de carbamazepina con anticoagulantes orales de acción directa (rivaroxaban, diabigratan, apixaban y edoxaban) puede…»

    AEMPS, section 4.5 · Open on CIMA

  • «Anticoagulantes orales de acción directa (ACOD): El anticoagulante oral de acción directa dabigatrán y edoxabán son sustratos del transportador de eflujo gp-P. Rivaroxabán y apixabán se metabolizan…»

    AEMPS, section 4.5 · Open on CIMA

  • ModerateCobicistat
    «Established and Other Potentially Significant Interactions: Anticoagulants: Direct Oral Anticoagulants (DOACs) apixaban rivaroxaban betrixaban dabigatran edoxaban ↑ apixaban TYBOST coadministered…»

    FDA, section 7 · Open on DailyMed

  • ModerateDarunavir
    «Established and Other Potentially Significant Drug Interactions: Anticoagulants : Direct Oral Anticoagulants (DOACs) apixaban rivaroxaban dabigatran etexilate edoxaban Other Anticoagulants warfarin ­…»

    FDA, section 7 · Open on DailyMed

  • ModeratePhenytoin
    «Drugs Affected by Phenytoin: Anticoagulants Apixaban, dabigatran, edoxaban, rivaroxaban»

    FDA, section 7 · Open on DailyMed

  • ModerateRitonavir
    «Anticoagulantes: Dabigatran etexilato Edoxaban … Las concentraciones séricas pueden aumentar debido a la inhibición de la P-gp por ritonavir. Debe considerarse la monitorización clínica y/o la…»

    AEMPS, section 4.5 · Open on CIMA

Check interaction with another drug

Opens the checker prefilled with this drug. Pick the second one from your regimen.

Open checker

Frequently asked

What is Edoxaban used for?

Edoxaban is evaluated for the following indications with varying evidence strength: Non-valvular atrial fibrillation (evidence tier A), Venous thromboembolism (evidence tier A), COVID-19 (evidence tier F). See the full indication matrix with dosing and citations above on this page.

What are the side effects of Edoxaban?

Common side effects of Edoxaban (≥ 1 in 100): Nosebleeds (7.7%), Blood in the urine (6.9%), Anemia (5.3%), Gastrointestinal, oral and pharyngeal bleeding, Bleeding into the skin, bleeding at puncture sites, Vaginal bleeding, heavier or longer periods. See the Safety section for uncommon and serious reactions.

Is Edoxaban safe during pregnancy?

Contraindicated in pregnancy (AEMPS ficha técnica, sections 4.3 and 4.6). Safety in pregnant women has not been established, edoxaban crosses the placenta, animal studies showed reproductive toxicity, and the drug carries its own bleeding risk. Women of childbearing potential should avoid pregnancy during treatment. If pregnancy is planned, the anticoagulant is changed in advance together with the doctor who manages the treatment.

Is Edoxaban compatible with breastfeeding?

Contraindicated during breastfeeding (AEMPS ficha técnica, sections 4.3 and 4.6). Safety during breastfeeding has not been established, and in animals edoxaban passes into milk. The choice is between stopping breastfeeding and stopping treatment. The FDA label also advises against breastfeeding during treatment because of the risk of bleeding in the infant.

Who should not take Edoxaban?

Edoxaban is contraindicated in: Hypersensitivity to edoxaban or any excipient; Active clinically significant bleeding; Liver disease with coagulopathy and clinically relevant bleeding risk; Lesions with a significant risk of major bleeding: active or recent gastrointestinal ulcer, malignancy at high bleeding risk, recent brain or spinal injury or surgery, recent eye surgery, recent intracranial hemorrhage, esophageal varices, arteriovenous malformations, aneurysms; Severe uncontrolled hypertension. Full list in the Safety section.

Does Edoxaban carry an FDA boxed warning?

FDA boxed warning (Savaysa): in non-valvular atrial fibrillation edoxaban should not be used with creatinine clearance above 95 mL/min, because in ENGAGE AF-TIMI 48 these patients had more ischemic strokes on 60 mg than on warfarin. Premature discontinuation of any oral anticoagulant without adequate alternative anticoagulation increases the risk of ischemic events. With neuraxial anesthesia or spinal puncture, epidural or spinal hematomas may occur and may cause long-term or permanent paralysis.

Official sources

Direct links to regulator labels. Open in a new tab.

How to cite

Vancouver

Edoxaban [Internet]. Evigrade; 2026 [updated 2026 Oct 30]. Available from: https://www.evigrade.com/en/drugs/edoxaban

APA 7

Evigrade. (2026, October 30). Edoxaban. https://www.evigrade.com/en/drugs/edoxaban

Other drugs in this group

Enoxaparin sodium, Nattokinase (serine protease from fermented soybean natto, Bacillus subtilis var. natto), Rivaroxaban, Ticagrelor, Acenocoumarol, Apixaban, Warfarin, Acetylsalicylic acid